Synthesis Of 5 Substituted 7-azaindoles And 7-azaindolines

  *US07652137B2*
  US007652137B2                                 
(12)United States Patent(10)Patent No.: US 7,652,137 B2
 Graczyk et al. (45) Date of Patent:Jan.  26, 2010

(54)Synthesis of 5 substituted 7-azaindoles and 7-azaindolines 
    
(75)Inventors: Piotr Pawel Graczyk,  London (GB); 
  Afzal Khan,  London (GB); 
  Gurpreet Singh Bhatia,  London (GB) 
(73)Assignee:Eisai R & D Management Co., Ltd., (JP), Type: Foreign Company 
(*)Notice: Subject to any disclaimer, the term of this patent is extended or adjusted under 35 U.S.C. 154(b) by 450 days. 
(21)Appl. No.: 10/548,162 
(22)PCT Filed:Mar.  5, 2004 
(86)PCT No.: PCT/GB2004/000946 
 § 371 (c)(1), (2), (4) Date: Mar.  13, 2006  
(87)PCT Pub. No.:WO20/04/078757 
 PCT Pub. Date:Sep.  16, 2004 
(65)Prior Publication Data 
 US 2006/0235042 A1 Oct.  19, 2006 
(30)Foreign Application Priority Data 
 Mar.  6, 2003     (GB)   0305142.2
(51)Int. Cl. C07D 471/04 (20060101)
(52)U.S. Cl. 546/14; 546/113
(58)Field of Search  546/14, 113

 
(56)References Cited
 
 U.S. PATENT DOCUMENTS
 4,719,218  A  1/1988    Bender et al.     
 5,439,917  A  8/1995    Briving et al.     
 5,714,495  A  2/1998    Viaud et al.     
 6,642,375  B2  11/2003    Inomata et al.     
 7,291,630  B2  11/2007    Graczyk et al.     
 7,314,940  B2  1/2008    Graczyk et al.     
 2002//0013354  A1  1/2002    Cheng et al.     
 2005//0272761  A1  12/2005    Graczyk et al.     
 2006//0235042  A1  10/2006    Graczyk et al.     
 2006//0270646  A1  11/2006    Graczyk et al.     
 2007//0072896  A1  3/2007    Khan et al.     

 
 FOREIGN PATENT DOCUMENTS 
 
       EP       0509974                         10/1992      
       EP       0 737 685                         10/1996      
       EP       1 106 621                         6/2001      
       JP       06247966                         9/1994      
       WO       WO-9/2/10498       A1                6/1992      
       WO       WO-9/2/10499       A1                6/1992      
       WO       WO-9/8/47899                         10/1998      
       WO       WO-9/9/20624                         4/1999      
       WO       WO-9/9/21859                         5/1999      
       WO       WO-9/9/51233                         10/1999      
       WO       WO-0/0/26210                         5/2000      
       WO       WO-0/0/26211                         5/2000      
       WO       WO-0/0/35909                         6/2000      
       WO       WO-0/0/35921       A1                6/2000      
       WO       WO-0/0/43393                         7/2000      
       WO       WO-0/0/56710                         9/2000      
       WO       WO-0/0/64449                         11/2000      
       WO       WO-0/0/64872                         11/2000      
       WO       WO-0/1/12609                         2/2001      
       WO       WO-0/1/47922                         7/2001      
       WO       WO-0/1/49288                         7/2001      
       WO       WO-0/2/10137                         2/2002      
       WO       WO-0/2/16359                         2/2002      
       WO       WO-0/2/081475                         10/2002      
       WO       WO-0/3/028724                         4/2003      
       WO       WO-0/3/082868                         10/2003      
       WO       WO-0/3/082869                         10/2003      
       WO       WO-2/004/016609                         2/2004      
       WO       WO-2/004/016610                         2/2004      
       WO       WO-2/004/078756                         9/2004      

 OTHER PUBLICATIONS
  
  Denmark et al., “Convergence of Mechanistic Pathways in the Palladium(0)-Catalyzed Cross-Coupling of Alkenylsilacyclobutanes and Alkenylsilanols”, Organic Letters. vol. 2, No. 16, pp. 2491-2494. (2000).
  Denamark et al., “Highly Stereospecific, Palladium-Catalyzed Cross-Coupling of Alkenylsilanols” Organic Letters vol. 2, No. 4, pp. 565-568 (2000).
  Greene, T. and Wuts, P., Protective Groups in Organic Synthesis, 3rd Edition, Wiley, New York (1999).
  Hatanaka et al., “Cross-Coupling of Organosilanes with Organic Halides Mediated by Palladium Catalyst and Tris(diethylamino)sulfonium Difluorotrimethylsilicate” J. Org. Chem 53 pp. 918-920 (1988).
  Hatanaka et al., “Highly Selective Cross-Coupling Reactions of Organosilicon Compounds Mediated by Fluoride Ion and a Palladium Catalyst”, Synlett pp. 845-853 (1991).
  Krasnokutskaya et al., Khim. Geterotsikl. Soed No. 3 pp. 380-384 (1977).
  Littke et al., “Versatile Catalysts for the Suzuki Cross-Coupling of Arylboronic Acids with Aryl and Vinyl Halides and Triflates under Mild Conditions” J. Am. Chem. Soc. 122 pp. 4020-4028 (2000).
  Littke et al., “Pd/P(t-Bu)3: A Mild and General Catalyst for Stille Reactions of Aryl Chlorides and Aryl Bromides” J. Am. Chem. Soc. 124 pp. 6343-6348 (2002).
  Martin et al., “Palladium-Catalyzed Cross-Coupling Reactions of Organoboronic Acids with Organic Electrophiles” Acta Chemica Scandinavica 47, pp. 221-230 (1993).
  Merour et al., Synthesis and Reactivity of 7-Azaindoles (1H-Pyrrolo[2,3-b]pyridine) Current Organic Chemistry 5 pp. 471-506 (2001).
  Mitchell, T. “Palladium-Catalysed Reactions of Organotin Compounds” Synthesis pp. 803-815 (1992).
  Stille, J.K,. “The Palladium-Catalyzed Cross-Coupling Reactions of Organotin Reagents with Organic Electrophiles” Angew. Chem. Int. Ed. Engl. 25 pp. 508-524 (1986).
  Suzuki, A. “Synthetic Studies via the Cross-Coupling Reaction of Organoboron Derivatives with Organic Halides” Pure Appl. Chem vol. 63, No. 3 pp. 419-422 (1991).
  Tamao et al., “Palladium-Catalyzed Cross-Coupling REaction of Alkenylalkosysilanes with Aryl and Alkenyl Halides in the Presence of a Fluoride Ion” Tetrahedron Letters, vol. 30, No. 44 pp. 6051-6054 (1989).
  Taylor et al., “Intramolecular Diels-Alder Reactions of 1,2,4-Triazines” Tetrahedron, vol. 43, No. 21 pp. 5145-5158 (1987).
  U.S. Appl. No. 10/591,551.
  U.S. Appl. No. 12/143,231.
  Adams et al. , Bioorg. Med. Chem. Lett. 2001, 11, 2867-2870.
  Alam et al., Synthesis and SAR of aminopyrimidines as novel c-Jun N-terminal kinase (JNK) inibitors:, Bioorg Med Chem Lett, vol. 17, pp. 3463-3467, 2007.
  Bundgaard, Design of ProDrugs, Elsevier Science Publishers 1985.
  Cao et al., “Distinct Requirements for p38α and c-Jun N-terminal Kinase Stress-activated Protein Kinases in Different Forms of Apoptotic Neuronal Death”, The Journal of Biological Chemistry, vol. 279, No. 34, pp. 35903-35913, Aug. 20 ,2004.
  CAS Accession No. 2001:432896, Registry No. 344454-31-1.
  CAS Document No. 135:107148.
  CAS document No. 135:43132.
  Corey, E.Jr., et. al.., A synthetic Method for Formyl-Ethynyl Conversion (RCHO—RC=CH or RC=CR′), Tetrahedron Letters No. 36, Aug. 1972.
  Database Beilstein, Beilstein Institute for Organic Chemistry, Citation No. 5563002 (1987).
  Dhar, et al., “The TosMIC Approach to 3-(Oxazol-5-yl) Indoles: Application to the Synthesis of Indole-Based IMPDH Inhibitors,” Bioorganic & Medicinal Chemistry Letters, 2002.
  Eilers et al., “Direct Inhibition of c-Jun N-terminal Kinase in Sympathetic Neurones Prevents c-jun Promoter Activation and NGF Withdrawal-induced Death”, Journal of Neurochemistry. vol. 76, pp. 1439-1454, 2001.
  Eilers et al., “Role of the Jun Kinase Pathway in the Regulation of c-Jun Expression and Apoptosis in Sympathetic Neurons”, The Journal of Neuroscience. vol. 18, No. 5, pp. 1713-1724, Mar. 1, 1998.
  Estus et al., “Aggregated Amyloid-β Protein Induces Cortical Neuronal Apoptosis and Concomitant “Apoptotic” Pattern of Gene Induction”, The Journal of Neuroscience, vol. 17, No. 20, pp. 7736-7745, Oct. 15, 1997.
  Golub et al., Science, vol. 286, pp. 531-537 Oct. 15, 1999.
  Guillard, et al. “Synthesis of New Maltonin Analogues from Dimers of Azaindole and Indole by Use of Suzuki Monocoupling”, Heterocycles, vol. 60, No. 4, pp. 865-877 (2003).
  Ham et al., “A c-Jun Dominant Negative Mutant Protects Sympathetic Neurons against Programmed Cell Death”, Neuron, Vol. 14, pp. 927-939, May 1995.
  Harper and LoGasso, Drugs of the Future 2001, 26, 957-973.
  Harper et al., “Inhibitors of the JNK Signaling Pathway”, Drugs of the Future, vol. 26, No. 10, pp. 957-973, 2001.
  Henry et al , Bioorg. Med. Chem. Lett. 1998, 8, 3335-3340.
  Houwing, et al., Preparation of N-Tosylmethylimino Compounds and their Use in the Synthesis of Oxazoles, Imidazoles and Pyrroles, Tetrahedron Letters No. 2, 1976.
  International Search Report for PCT/GB2004/002099, mailed Dec. 2, 2004, 4 pages.
  International Search Report for PCT/GB2005/000779, mailed Aug. 12 , 2005, 4 pages.
  Kruber, Caplus, Copyright 2007 ACS on STN, 2 pages.
  Kumar et al, “Synthesis of 7-Azaindole and 7-Azaoxindole Derivatives through a Palladium-Catalyzed Cross Coupling Reaction”, J. Org. Chem, 57, pp. 6995-6998 (1992).
  Lecointe, Reach-trhough Claims, International Pharmaceutical (2002)(also available at <http:///www.bakerbotts.com/infocenter/publications/detail.aspx?id=bffe4a7d-5beb-4cf8-a189-15a190f0eb>).
  Lisnock et al., “Activation of JNK3α1 Requires Both MKK4 and MKK7: Kinetic Characterization of in Vitro Phosphorylated JNK3α1”, Biochemistry, vol. 39, pp. 3141-3149, 2000.
  Mettey, et al., “Aloisines, a New Family of CDK/GSK-3 Inhibitors. SAR STudy, Crystal Structure in Complex with CDK2, Enzyme Selectivity and Cellular Effects”, J. Med. Chem, 46, pp. 222-236 (2003).
  Park et al, “A FAcile Synthesis of 2,3-Disubstitute Pyrrolo[2,3-b]pyridines via Palladium-Catalyzed Heteroannulation with Internal Alkynes”, Tetrahedron Letters 39, pp. 627-630 (1998).
  Pisano et al, “Bis-indols: a Novel Class of Molecules Enhancing the Cytodifferentiating Properties of Retinoids in Myeloid Leukemia Cells”, Blood, vol. 100, No. 10, pp. 3719-3730 (2002).
  Resnick, et al. “Targeting JNK3 for the Treatment of Meurodegenerative Disorders”, Drug Discovery Today, Elsevier Science LTD. 9:21 (2004) pp. 932-939.
  Silva, “Reach through Claims: Bust or Boon?”, Intellectual Property Update (available at <http://www.dorsey.com/publlications/legaldetail.aspx?FlashNavID=pubslegal&pubid=170565003>).
  Smulik and Diver, “Synthesis of Cyclosporin A-Derived Affinity Reagents by Olefin Metathesis”, Organic Letters, vol. 4, No. 12, pp. 2051-2054, 2002.
  Van Leusen, et al., Chapter 3: Synthetic Uses of Tosylmethyl Isocyanide (TosMIC), Organic Reactions, vol. 57, 2001.
  Vippagunta et al., “Crystalline Solids”, Advanced Drug Delivery Reviews, vol. 48, No. 1; pp. 3-26, 2001.
  Watson et al., “Phosphorylation of c-Jun is Necessary for Apoptosis Induced by Survival Signal Withdrawal in Cerebellar Granule Neurons”, The Journal of Neuroscience, vol. 18, No. 2, pp. 751-762, Jan. 15, 1998.
  West, Anthony R., “Solid State Chemistry and its Applications”, Wiley, NY 1988.
  Witherington et al., “5-Aryl-pyrazolo [3,4-b]pyridines: Potent Inhibitors of Glycogen Synthase Kinase-3 (GSK-3)”, Bioorganic & Medicinal Chemistry Letters 13, pp. 1577-1580 (2003).
  Young et al., “Pyridinyl Imidazole Inhibitors of p38 Mitogen-activated Protein Kinase Bind in the ATP Site”, The Journal of Biological Chemistry, vol. 272, No. 18, pp. 12116-12121, May 2, 1997.
  Zevaco, T. et al., Bismuth (III) Pyridine—and Pyrazine-Carboxylates, New J. Chem.., vol. 15, pp. 927-930, 1991.
  Kontoyiannis et al., “Imparied On/Off Regulation of TNF Biosynthesis in Mice Lacking TNF AU-Rich Elements: Implications for Joint and Gut-Associated Immunopathologies”, Immunity, (1999 Mar) vol. 10, pp. 387-398.
  Leroy et al., “Homochiral NADH models in the pyrrolo[2,3-b]pyridine series bearing one or two chiral auxiliaries. Asymmetric reduction of methyl benzoylformate and N-acetyl-enamines. Influence of the magnesium salt concentration on the asymmetric induction of reductions.” Tetrahedron: Asymmetry, vol. 8, No. 19, pp. 3309-3318, 1997.
  Han, Z. et al., “Jun N-Terminal Kinase in Rheumatoid Arthritis,” J. of Pharmacol. Exper. Therap. 291(1): 124-130 (1999).
  Kontoyiannis et al., Immunity, (1999 Mar) vol. 10, No. 3, pp. 387-398.
  Leroy et al., Tetrahedron: Asymmetry (1997), 8(19), 3309-3318.
  Peng, J. and Andersen, J.K., “The Role of c-Jun N-Terminal Kinase (JNK) in Parkinson's Disease,” Life 55(4-5): 267-271, Apr.-May 2003.
 
     Primary Examiner —Patricia L Morris
     Art Unit — 1625
     Exemplary claim number — 1
 
(74)Attorney, Agent, or Firm — Wilmer Cutler Pickering Hale & Dorr LLP.

(57)

Abstract

The present invention provides a novel substituted azaindoline intermediate of formula (I) and a method for its synthesis. The novel substitued azaindoline intermediate (I) is provided for use in the manufacture of 5-substituted 7-azaindolines and 5-substituted 7-azaindoles.
[see pdf for image]
9 Claims, Drawing Sheets, and Figures
 
 
[0001] The present invention provides a novel substituted azaindoline intermediate and a method for its synthesis. The invention further provides the use of the intermediate in the manufacture of 5-substituted 7-azaindolines and 5-substituted 7-azaindoles.
[0002] The 7-azaindole system forms the core structure of various pharmaceutically important substances such as antitumour agents, ligands of melatoninergic receptor, dopamine D4 receptors, serotonin receptor, 5-HT6 receptor, p38 kinase inhibitors, renin inhibitors, thrombin inhibitors, and antitussive agents. Furthermore, antifungal activity of some 7-azaindoles in plant systems has recently been discovered.
[0003] Synthesis and reactivity of 7-azaindoles has recently been extensively reviewed (Merour and Joseph Current Org. Chem. 2001, 5, 471). Functionalization of the 7-azaindole system at position 5 is a fundamental transformation used in the synthesis of melatoninergic ligands and JNK inhibitors. Such functionalization is achieved by initial installation of the bromine atom at position 5, which is considered to be the key step in each of these synthetic routes. However, despite the importance of this process, the most widely used approach to introduce the bromine atom in position 5 requires dibromide (2) as an intermediate (Scheme 1). The two bromine atoms at C(3) serve as temporary and expensive temporary protection against bromination of the five-membered ring.
[0004] Synthesis of dibromide (2) is troublesome due to the use of large excess of pyridinium perbromide (4 equivalents) and difficult workup procedure. If direct conversion of (1) into (3) is undertaken, large excess of bromine—usually over 12 molar equivalents is required.
[0005]  [see pdf for image]
[0006] Furthermore, the subsequent reductive debromination of (3) to afford (4) is conducted with 10-fold excess of zinc in acetic acid or excess of saturated aqueous solution of ammonium chloride, which results in difficult workup and creation of large amount of waste. Compound (4), thus prepared has limited applicability for further functionalizations.
[0007] The transformations known in the art are presented schematically in Scheme 2. Compound (4) can be converted to 5-bromo-7-azaindole (6) via 5-bromo-7-azaindoline (5) and then to the relevant 5-methoxy derivative (7), and may also undergo palladium-catalyzed Suzuki and Stille couplings and carbonylation to afford (8), (9), and (10), respectively.
[0008]  [see pdf for image]
[0009] It should be emphasized that reactivity of 5-bromo-7-azaindole (6) in the palladium-catalysed coupling reactions like Suzuki and Stille reactions has not been reported, yet.
[0010] Sometimes the problems with installation of substituents at position 5 of the 7-azaindole system are circumvented by linking the desired group to the pyridine ring and subsequently closing the pyrrole ring to form the 7-azaindole system as shown below in Scheme 3 (X is usually halogen).
[0011]  [see pdf for image]
[0012] A similar method leading to the 7-azaindoline system (14) (which may be converted to the 7-azaindole skeleton) is based on the intramolecular Diels-Alder reaction of properly functionalised amino pyrimidines (13) (Scheme 4; R═H, NO2).
[0013]  [see pdf for image]
[0014] Diels-Alder reaction of properly functionalised 1,2,4-triazines (15) (Scheme 5) may also lead to the 7-azaindoline skeleton (16), but the method works best in the absence of substituent at C(5), i.e. R═H.
[0015]  [see pdf for image]
[0016] These processes involve many synthetic steps, utilize difficult to synthesize intermediates and/or costly palladium catalysts. Furthermore, all the methods described above allow only a limited scope of substituents to be introduced at C(5). For instance, many substituents easily accessible via carboanion chemistry, like —CH(O)R, —SiR3, —SnR3, have not been explored at all due to unavailability of synthetic methodology leading to 5-lithio-7-azaindole/azaindoline.
[0017] Synthesis of the unsubstituted 7-azaindoline starting material has previously involved harsh conditions. Previous attempts to obtain the 7-azaindoline has involved high pressure hydrogenation of 7-azaindole at 200° C., hydrogenation over Pd/δ-Al2O3 at 150° C. and under 450 psi pressure and hydrogenation over Pd/C in neat trifluoroacetic acid under 50 psi. Such reduction methods are hindered as the hydrogenolysis of 7-azaindole in the acidic medium catalysed by PtO2 may lead to overreduction
[0018] Derivatisation of the 7-azaindoline system obtained by the methods above is limited. Subsequent bromination of 7-azaindoline system (17) (Scheme 6) using dioxane dibromide, NBS or bromine to give bromide (5) is known. Limited functionalization of (5) to the cyano derivative (18) has also been presented.
[0019]  [see pdf for image]
[0020] Similar transformation involving a N-protected azaindoline (19) (Scheme 7) has also been described.
[0021]  [see pdf for image]
[0022] However, the nitrogen protecting group used in 5-bromo-7-azaindoline (19), benzyloxycarbonyl (Cbz), although easy to install, has a limited resistance. In particular it is unsuitable for reactions involving strong bases such as n-BuLi, sec-BuLi, tert-BuLi, NaNH2, and Grignard reagents. Such reactions, especially with alkyllithiums, could open a novel way for derivatization of the 7-azaindole system at C(5). However, the use of other protecting groups to protect the 5-bromo-7-azaindoline system is unknown in the art.
[0023] The production of 5-substituted-7-azaindoles therefore provides a number of problems in the art. There is therefore a need in the art for new methods of preparing such compounds.
[0024] To avoid the problems associated with the current state-of-the-art methods and to open new possibilities for functionalization of position 5 of the 7-azaindole system, the present invention provides the use of functionalised 7-azaindoline derivatives as key intermediates. These intermediates can be rearomatized with DDQ to 7-azaindoles avoiding the use of heavy metal oxidants such as Mn(OAc)3 or MnO2 (cf Scheme 2). The ability to avoid the use of heavy metal oxidants is particularly important when the resulting 5-functionalised-7-azaindoles are used in medicine.
[0025] Attempts have previously been made to use DDQ for similar purposes. However the obtained yields for rearomatization of unprotected 7-azaindolines were prohibitively low, (i.e. below 50%) indicating that the use of DDQ was not viable in a commercial synthesis (Taylor et al. Tetrahedron 1987, 43, 5145). The present invention demonstrates that proper choice of protecting group, in particular the electron-donating silyl group, allows this process to occur in a quantitative yield. The present invention therefore provides a method of rearomatization which can be used on an industrial scale and eliminates unwanted heavy metal residues in the product. Furthermore, the present invention further provides a new, simple method to synthesise the starting unsubstituted 7-azaindoline, which avoids using harsh conditions described in the literature. The present invention therefore provides a significant advance in the production of 5-functionalised-7-azaindoles.
[0026] The first aspect of the present invention provides a compound of formula (I)
[0027]  [see pdf for image]
wherein X is an amino-protecting group, with the proviso that X is not benzyloxycarbonyl (Cbz).
[0028] In particular, X is preferably selected from R1S(O)2, (R1)3Si, R1C(O), R1OCH2, R12NSO2, R1OC(O)—, R1(R1O)CH—, R1CH2CH2—, R1CH2—, PhC(O)CH2—, CH2═CH—, ClCH2CH2—, Ph3C—, Ph2(4-pyridyl)C—, Me2N—, HO—CH2—, R1OCH2—, (R1)3SiOCH2—, (R1O)2CH—, t-BuOC(O)CH2—, Me2NCH2— and tetrahydropyranylamine;
[0029] wherein R1 is C1-6 alkyl, C3-12 cycloalkyl, C1-6 haloalkyl, C6-12 heterocyclyl or C6-12carbocyclyl; optionally substituted with one or more of C1-6 alkyl, Si(R3)3, OR3, NO2, CO2, CO2R3, halogen, haloalkyl, SR3, CN, NR3COR3, COR13CONR3R3,
[0030] wherein R3 is hydrogen or C1-6 alkyl, preferably R1 is methyl, ethyl, propyl, n-butyl, tert-butyl or phenyl, with the proviso that when X is R1OC(O)—, R1 is not PhCH2.
[0031] When X is a dialkylsulfonamide (R12NSO2—), R1 is preferably alkyl, more preferably methyl. When X is a carbamate (R1OC(O)—) R1 is preferably alkyl, cycloalkyl, aryl or heteroaryl, more preferably CCl3CH2, Me3SiCH2CH2, t-butyl, 2,4-dimethylpent-3-yl, cyclohexyl, CCl3Me2COC(O), 1-adamantyl, 2-adamantyl or cyclohexyl. When X is N-(1-alkoxy)ethylamine (R1(R1O)CH—), R1 is preferably alkyl, more preferably Me or Et. When X is N-2-(hetero)arylethylamine (R1CH2CH2—), R1 is preferably aryl or heteroaryl, more preferably 2-pyridyl, 4-pyridyl or 4-nitrophenyl. When X is arylmethylamine (R1CH2—), R1 is aryl or heteroaryl, more preferably Ph-, p-methoxyphenyl-, 3,4-dimethoxyphenyl, 3-methoxyphenyl, 3,5-dimethoxyphenyl, 2-nitrophenyl or 2,4-dinitrophenyl. When X is N-alkoxymethylamine (R1OCH2—), R1 is alkyl, more preferably methyl, ethyl, ClCH2CH2—, Me3SiCH2CH2—, t-butyl or PhCH2—.
[0032] When X is N-silyloxymethylamine ((R1)3SiOCH2—), R1 is alkyl, more preferably methyl or t-butyl. When X is N-dialkoxymethylamine ((R1O)2CH—), R1 is alkyl, more preferably methyl or ethyl. When X is sulfonamide (R1S(O)2—), R1 is preferably 2,4,6-trimethylphenyl (mesityl), 4-methoxyphenyl, phenyl or toluyl.
[0033] Such protecting groups must not deactivate the pyridine ring towards bromination, and must withstand the conditions of the subsequent reactions, in particular these involving carboanion chemistry. X is therefore most preferably a silyl group (especially t-butyldimethylsilyl (TBS), triisopropylsilyl (TIPS) or t-butyldimethylphenylsilyl (TBDPS)), N-alkoxymethylamine (R1OCH2—) wherein R1 is preferably methyl or a sulfonamide R1S(O)2 wherein R1 is preferably phenyl, methoxymethyl (MOM) or ethoxymethyl.
[0034] Compound (I) of the present invention is a versatile intermediate and allows the production of many 5-substituted 7-azaindoles.
[0035] The second aspect of the invention provides a method for synthesising a compound of formula (I) comprising brominating a compound of formula (II);
[0036]  [see pdf for image]
wherein X is a amino-protecting group as defined in the first aspect of the invention.
[0037] In a preferred feature of the second aspect, X is preferably selected from (R1)3Si or R1OCH2, wherein R1 is C1-6 alkyl or C6-12 aryl, preferably methyl, ethyl, propyl n-butyl, tert-butyl or phenyl.
[0038] In a preferred feature of the second aspect, X is (R1)3Si and R1 is independently C1-6 alkyl or C6-12 aryl, preferably methyl, ethyl, propyl, n-butyl, tert-butyl or phenyl.
[0039] Bromination can be carried out using reagents and conditions known in the art. The reagents are preferably Br2, dioxane dibromide, pyridinium perbromide or NBS.
[0040] For the purposes of this invention, a compound of formula (II) can be provided from azaindoline using reagents and methods well known in the art. Protecting groups such as benzyl, acetamide, benzyl carbamate or p-toluenesulfonamide can be installed using standard methods known in the art, which are described in T. W. Greene and P. G. M. Wuts Protective Groups in Organic Synthesis 3rd Edn., Wiley, New York 1999; pages 494-626.
[0041] Alternatively, the protecting group X can be introduced prior to the formation of the azaindole skeleton, as illustrated below wherein the p-toluenesulfonyl group is linked to the nitrogen of the 7-azaindole system as a result of the reaction between N-tosylaziridine and malonodinitrile (Chemische Berichte 1985, 118, 4473).
[0042]  [see pdf for image]
[0043] An alternative method of producing a compound of formula (I) involves the protection of a compound of formula (III) as illustrated.
[0044]  [see pdf for image]
wherein X is selected from R1S(O)2, (R1)3Si, R1C(O), R1OCH2, R12NSO2, R1OC(O)—, R1(R1O)CH—, R1CH2CH2—, R1CH2—, PhC(O)CH2—, CH2═CH—, ClCH2CH2—, Ph3C—, Ph2(4-pyridyl)C—, Me2N—, HO—CH2—, R1OCH2—, (R1)3SiOCH2—, (R1O)2CH—, t-BuOC(O)CH2—, Me2NCH2— and tetrahydropyranylamine;
[0045] wherein R1 is C1-6 alkyl, C3-12 cycloalkyl, C1-6 haloalkyl, C6-12 heterocyclyl or C6-12 carbocyclyl; optionally substituted with one or more of C1-6 alkyl, Si(R3)3, OR3, NO2, CO2, CO2R3, halogen, haloalkyl, SR3, CN, NR3COR3, COR13CONR3R3,
[0046] wherein R3 is hydrogen or C1-6 alkyl, preferably R1 is methyl, ethyl, propyl, n-butyl, tert-butyl or phenyl.
[0047] The compound of formula (III) can be produced from azaindoline using reagents and methods well known in the art. Examples of such brominations are indicated in Krasnokutskaya et al. Khim. Geterotsikl. Soed. 1977, 3, 380, WO00/26210, WO00/26211, WO00/64449, Taylor et al. Tetrahedron, 1987, 43, 5145.
[0048] The third aspect of the invention provides a method for the production of a compound of formula (IV)
[0049]  [see pdf for image]
comprising the metal-halogen exchange with a metal of formula M(R2)n, wherein each R2 is independently OH, C1-6 alkyl, C1-6 alkoxy, halo or C6-12 carbocyclyl,
[0050] X is selected from R1S(O)2, (R1)3Si, R1C(O), R1OCH2, R12NSO2, R1OC(O)—, R1(R1O)CH—, R1CH2CH2—, R1CH2—, PhC(O)CH2—, CH2═CH—, ClCH2CH2—, Ph3C—, Ph2(4-pyridyl)C—, Me2N—, HO—CH2—, R1OCH2—, (R1)3SiOCH2—, (R1O)2CH—, t-BuOC(O)CH2—, Me2NCH2— and tetrahydropyranylamine;
[0051] wherein R1 is C1-6 alkyl, C3-12 cycloalkyl, C1-6 haloalkyl, C6-12 heterocyclyl or C6-12 carbocyclyl; optionally substituted with one or more of C1-6 alkyl, Si(R3)3, OR3, NO2, CO2, CO2R3, halogen, haloalkyl, SR3, CN, NR3COR3, COR13CONR3R3,
[0052] wherein R3 is hydrogen or C1-6 alkyl, preferably R1 is methyl, ethyl, propyl, n-butyl, tert-butyl or phenyl
[0053] n is 1, 2, 3 or 4, and M is Li, Sn, B, Mg, Zn, In, Cu, Zr, or Pd.
[0054] In a preferred feature of the reaction, the compound of formula (IV) may undergo one or more further transmetalation reactions for example by incubation with a metal halide such as ZnCl2, MgCl2, PdCl2, or (R2)3SnW wherein R2 is C1-12 alkyl, preferably methyl or butyl and W is halogen preferably Cl or I. Preferred examples of metal halides having the formula (R2)3SnW include Bu3SnI or Me3SnCl.
[0055] The fourth aspect of the invention provides a compound of formula (IV)
[0056]  [see pdf for image]
wherein each R2 is independently —OH, C1-6 alkyl, C1-6 alkoxy, halo or C6-12 carbocyclyl, n is 1, 2, 3 or 4, M is a metal preferably selected from Li, Sn, B, Mg, Zn, In, Cu, Zr, Pd or Zn and X is a amino-protecting group, preferably selected from R1S(O)2, (R1)3Si, R1C(O), R1OCH2, R12NSO2, R1OC(O)—, R1(R1O)CH—, R1CH2CH2—, R1CH2—, PhC(O)CH2—, CH2═CH—, ClCH2CH2—, Ph3C—, Ph2(4-pyridyl)C—, Me2N—, HO—CH2—, R1OCH2—, (R1)3SiOCH2—, (R1O)2CH—, t-BuOC(O)CH2—, Me2NCH2— and tetrahydropyranylamine;
[0057] wherein R1 is C1-6 alkyl, C3-12 cycloalkyl, C1-6 haloalkyl, C6-12 heterocyclyl or C6-12 carbocyclyl; optionally substituted with one or more of C1-6 alkyl, Si(R3)3, OR3, NO2, CO2, CO2R3, halogen, haloalkyl, SR3, CN, NR3COR3, COR13CONR3R3,
[0058] wherein R3 is hydrogen or C1-6 alkyl, preferably R1 is methyl, ethyl, propyl, n-butyl, tert-butyl or phenyl.
[0059] In a preferred feature of the fourth aspect, M can represent a metal such as Li, or metal alkyl group such as Sn(R2)3 wherein R2 is a C1-12 alkyl.
[0060] The fifth aspect of the invention provides a method for the production of a compound of formula (V)
[0061]  [see pdf for image]
comprising incubating a compound of formula (I) with a base and (R4)3SiZ wherein R4 is a C1-6 alkyl, OH, or an C6-12 aryl group, Z is a halide preferably chloride or bromide and X is an amino-protecting group, preferably selected from R1S(O)2, (R1)3Si, R1C(O), R1OCH2, R12NSO2, R1OC(O)—, R1(R1O)CH—, R1CH2CH2—, R1CH2—, PhC(O)CH2—, CH2═CH—, ClCH2CH2—, Ph3C—, Ph2(4-pyridyl)C—, Me2N—, HO—CH2—, R1OCH2—, (R1)3SiOCH2—, (R1O)2CH—, t-BuOC(O)CH2—, Me2NCH2— and tetrahydropyranylamine;
[0062] wherein R1 is C1-6 alkyl, C3-12 cycloalkyl, C1-6 haloalkyl, C6-12 heterocyclyl or C6-12 carbocyclyl; optionally substituted with one or more of C1-6 alkyl, Si(R3)3, OR3, NO2, CO2, CO2R3, halogen, haloalkyl, SR3, CN, NR3COR3, COR13CONR3R3,
[0063] wherein R3 is hydrogen or C1-6 alkyl, preferably R1 is methyl, ethyl, propyl, n-butyl, tert-butyl or phenyl.
[0064] For the purposes of the fifth aspect, the base is preferably t-BuLi.
[0065] The sixth aspect of the invention provides a compound of formula (V)
[0066]  [see pdf for image]
wherein R4 is a C1-6 alkyl, OH, or an C6-12 aryl group, X is an amino-protecting group, preferably selected from R1S(O)2, (R1)3Si, R1C(O), R1OCH2, R12NSO2, R1OC(O)—, R1(R1O)CH—, R1CH2CH2—, R1CH2—, PhC(O)CH2—, CH2═CH—, ClCH2CH2—, Ph3C—, Ph2(4-pyridyl)C—, Me2N—, HO—CH2—, R1OCH2—, (R1)3SiOCH2—, (R1O)2CH—, t-BuOC(O)CH2—, Me2NCH2— and tetrahydropyranylamine;
[0067] wherein R1 is C1-6 alkyl, C3-12 cycloalkyl, C1-6 haloalkyl, C6-12 heterocyclyl or C6-12 carbocyclyl; optionally substituted with one or more of C1-6 alkyl, Si(R3)3, OR3, NO2, CO2, CO2R3, halogen, haloalkyl, SR3, CN, NR3COR3, COR13CONR3R3,
[0068] wherein R3 is hydrogen or C1-6 alkyl, preferably R1 is methyl, ethyl, propyl, n-butyl, tert-butyl or phenyl.
[0069] The seventh aspect of the invention provides a method of producing a compound of formula (VI)
[0070]  [see pdf for image]
comprising incubating a compound of formula (I) with boronate (R5)3B, (R5)2B—H or (R5)2B—B(R5)2 and a base or a palladium catalyst such as PdCl2 or PdCl2(1,1′-bis(diphenylphosphino) ferrocene), wherein R5 is OH or a group OR20 wherein R20 is C1-6 alkyl or C6-12 aryl and wherein two or more R20 groups may together form a 4 to 7 membered ring, and wherein X is an amino-protecting group, preferably selected from R1S(O)2, (R1)3Si, R1C(O), R1OCH2, R12NSO2, R1OC(O)—, R1(R1O)CH—, R1CH2CH2—, R1CH2—, PhC(O)CH2—, CH2═CH—, ClCH2CH2—, Ph3C—, Ph2(4-pyridyl)C—, Me2N—, HO—CH2—, R1OCH2—, (R1)3SiOCH2—, (R1O)2CH—, t-BuOC(O)CH2—, Me2NCH2— and tetrahydropyranylamine;
[0071] wherein R1 is C1-6 alkyl, C3-12 cycloalkyl, C1-6 haloalkyl, C6-12 heterocyclyl or C6-12 carbocyclyl; optionally substituted with one or more of C1-6 alkyl, Si(R3)3, OR3, NO2, CO2, CO2R3, halogen, haloalkyl, SR3, CN, NR3COR3, COR13CONR3R3,
[0072] wherein R3 is hydrogen or C1-6 alkyl, preferably R1 is methyl, ethyl, propyl, n-butyl, tert-butyl or phenyl.
[0073] More preferably, boronate is selected from H—B(OR15)2, (Me2C—O)2B—B(O—CMe2)2 and B(OR15)3.
[0074] In a preferred feature of the seventh aspect, the production of a compound of formula (VI) can be catalysed by the addition of a metal catalyst. In particular, the formation of a compound of formula (VI) can be catalysed by a palladium catalyst such as PdCl2 or PdCl2(1,1′-bis(diphenylphosphino) ferrocene)
[0075] Example of such a boronation reaction is indicated below,
[0076]  [see pdf for image]
[0077] The eighth aspect of the invention provides a compound of formula (VI)
[0078]  [see pdf for image]
wherein R5 is OH, or a group OR20 wherein R20 is C1-6 alkyl or C6-12 aryl and wherein two or more R20 groups may together form a 4 to 7 membered ring, and X is a amino-protecting group, preferably selected from R1S(O)2, (R1)3Si, R1C(O), R1OCH2, R12NSO2, R1OC(O)—, R1(R1O)CH—, R1CH2CH2—, R1CH2—, PhC(O)CH2—, CH2═CH—, ClCH2CH2—, Ph3C—, Ph2(4-pyridyl)C—, Me2N—, HO—CH2—, R1OCH2—, (R1)3SiOCH2—, (R1O)2CH—, t-BuOC(O)CH2—, Me2NCH2— and tetrahydropyranylamine;
[0079] wherein R1 is C1-6 alkyl, C3-12 cycloalkyl, C1-6 haloalkyl, C6-12 heterocyclyl or C6-12 carbocyclyl; optionally substituted with one or more of C1-6 alkyl, Si(R3)3, OR3, NO2, CO2, CO2R3, halogen, haloalkyl, SR3, CN, NR3COR3, COR13CONR3R3,
[0080] wherein R3 is hydrogen or C1-6 alkyl, preferably R1 is methyl, ethyl, propyl, n-butyl, tert-butyl or phenyl.
[0081] More preferably B(R5)2 represents a pinacol ester
[0082] The ninth aspect of the invention provides a method for the production of a compound of formula (VII)
[0083]  [see pdf for image]
comprising a) reaction of a compound of formula (IV) with an electrophile, or b) reaction of a compound of formula (IV) with R6-Z in the presence of a palladium catalyst or c) reaction of a compound of formula (V) with R6-Z in the presence of a palladium catalyst or d) reacting a compound of formula (VI) with R7-Z in the presence of a palladium catalyst;
[0084] wherein R8 is an optionally substituted C1-12 alkyl, C2-12 alkenyl, COR9 carbocyclyl or heterocyclyl group;
[0085] wherein R9 is optionally subsituted alkyl, carbocyclyl or heterocyclyl; and
[0086] wherein, each substitutable carbon atom in R8 or R9 is optionally and independently substituted by one or more of C1-12 alkyl, C2-12 alkenyl, carbocyclyl, or heterocyclyl, halogen, haloalkyl, OR10, SR10, NO2, CN, NR10R10, NR10COR10, NR10CONR10R10, NR10CO2R10, CO2R10, COR10, CONR10R10, S(O)2R10, SONH2, S(O)R10, SO2NR10R10, NR10S(O)2R10, wherein each R10 may be the same or different and is as defined below; wherein the C1-12 alkyl optionally incorporates one or two insertions selected from the group consisting of —O—, —C(O)—, —N(R10)—, —S(O)— and —S(O2)— and wherein the C1-12 alkyl, carbocyclyl, or heterocyclyl group is optionally substituted by one or more of halogen, haloalkyl, OR10, SR, NO2, CN, NR10R10, NR10COR10, NR10CONR10R10, NR10COR10, NR10CO2R10, CO2R10, COR10, CONR102, S(O)2R10, SONH2, S(O)R10, or NR10S(O)2R10;
[0087] each substitutable nitrogen atom in R8 is optionally substituted by R11, COR10, SO2R10 or CO2R10, wherein each R10 and R11 may be the same or different and is as defined below;
[0088] the optionally substituted carbocyclyl or optionally substituted heterocyclyl group is optionally fused to an unsaturated, partially unsaturated or fully saturated five to seven membered ring containing zero to three heteroatoms, each saturated carbon in the optional fused ring is further optionally and independently substituted by ═O, ═S, ═NNHR10, NNR10R10, ═N—OR10, ═NNHCOR10, ═NNHCO2R10, ═NNSO2R10, or ═NR10, wherein each R10 may be the same or different and is as defined below;
[0089] R10 is hydrogen, C1-12 alkyl or aryl, optionally substituted by one or more of C1-4 alkyl, halogen, C1-4 haloalkyl, OR12, SR12, NO2, CN, NR12R12, NR12COR12, NR12CONR12R12, NR12COR12, NR12CO2R12, CO2R12, COR12, CONR122, S(O)2R12, SONH2, S(O)R12, SO2NR12R12, NR12S(O)2R12, wherein the C1-12 alkyl group optionally incorporates one or two insertions selected from the group consisting of —O—, —N(R12)—, —S(O)— and —S(O2)—, wherein each R12 may be the same or different and is as defined below;
[0090] R11 is C1-12 alkyl or aryl, optionally substituted by one or more of C1-4 alkyl, halogen, C1-4 haloalkyl, OR12, SR12, NO2, CN, NR12R12, NR12COR12, NR12CONR12R12, NR12COR12, NR12CO2R12, CO2R12, COR12, CONR122, S(O)2R12, SONH2, S(O)R12, SO2NR12R12, NR12S(O)2R12, wherein the C1-12 alkyl group optionally incorporates one or two insertions selected from the group consisting of —O—, —N(R12)—, —S(O)— and —S(O2)—, wherein each R12 may be the same or different and is as defined below;
[0091] R12 is hydrogen, C1-4 alkyl, or C1-4 haloalkyl;
[0092] wherein X is a amino-protecting group, preferably selected from R1S(O)2, (R1)3Si, R1C(O), R1OCH2, R12NSO2, R1OC(O)—, R1(R1O)CH—, R1CH2CH2—, R1CH2—, PhC(O)CH2—, CH2═CH—, ClCH2CH2—, Ph3C—, Ph2(4-pyridyl)C—, Me2N—, HO—CH2—, R1OCH2—, (R1)3SiOCH2—, (R1O)2CH—, t-BuOC(O)CH2—, Me2NCH2— and tetrahydropyranylamine;

wherein R1 is C1-6 alkyl, C3-12 cycloalkyl, C1-6 haloalkyl, C6-12 heterocyclyl or C6-12 carbocyclyl; optionally substituted with one or more of C1-6 alkyl, Si(R3)3, OR3, NO2, CO2, CO2R3, halogen, haloalkyl, SR3, CN, NR3COR3, COR13CONR3R3,

[0093] wherein R3 is hydrogen or C1-6 alkyl, preferably R1 is methyl, ethyl, propyl, n-butyl, tert-butyl or phenyl.
[0094] wherein R6 and R7 are independently selected from an optionally substituted C1-12 alkyl, C2-12 alkenyl, COR9, carbocyclyl or heterocyclyl group and Z is a halogen preferably iodine, bromide or chlorine, or triflate.
[0095] In a preferred feature of the ninth aspect, R8 is preferably substituted with one or more of alkyl (e.g. methyl, ethyl or propyl), haloalkyl (preferably CF3), halogen (e.g. F, Cl or Br, preferably F), OR13, SR13, SOR13, N(R13)2, wherein R13 is independently selected from hydrogen, C1-4 alkyl or haloalkyl and is preferably phenyl or napthyl. When R8 is phenyl it is preferably substituted in the 4-(para) position, by NR14R14, where R14 is independently H or C1-4 alkyl.
[0096] For the avoidance of doubt, when a group as defined above contains two or more radicals, e.g. the radical R10, as for example in the groups SO2NR10R10 and NR10COR10, the two or more radicals e.g. R10 may be the same or different.
[0097] It will be appreciated that the reaction set out as option b) for the ninth aspect is a Stille reaction, which can be carried out according to Stille Angew. Chem., Int.ed, Engl. 1986, 25, 508; Mitchell Synthesis, 1992, 803, or Littke et al. J. Am. Chem. Soc. 2002, 124, 6343.
[0098] It will be appreciated that the reaction set out as option c) for the ninth aspect is a Hiyama reaction which can be carried out according to Hatanaka et al. J. Org. Chem. 1988, 53, 918, Hatanaka et al. Synlett, 1991, 845 or Tamao et al. Tetrahedron Lett. 1989, 30, 6051, or Denmark et al. Org. Lett. 2000, 2, 565, ibid. 2491.
[0099] The reaction set out as option d) for the ninth aspect is a Suzuki reaction which can be carried out according to Suzuki Pure Appl. Chem. 1991, 63, 419, or Littke J. Am. Chem. Soc. 2000, 122, 4020.
[0100] For the purposes of this invention, a compound of formula (IV) is preferably incubated with an electrophile such as a C1-12 alkyl halide for example methyl iodide, DMF, CO2, or a group R10—C(O)H wherein R10 is C1-12 alkyl or C6-12 aryl.
[0101] In a preferred feature of the ninth aspect, a compound of formula (VII) is produced by the palladium-catalysed coupling reaction between a stannane of formula (VIII) and a group R8—Y wherein R8 is a group as defined above and Y is a halogen,
[0102]  [see pdf for image]
[0103] Compound (VIII) is formed by the transmetallation of a compound of formula (I) or (IV) as described in the third aspect of the invention.
[0104] For the purposes of all aspects of this invention, alkyl relates to both straight chain and branched alkyl radicals of 1 to 12 carbon atoms, preferably 1 to 8 carbon atoms and most preferably 1 to 4 carbon atoms including but not limited to methyl, ethyl, n-propyl, isopropyl, n-butyl, sec-butyl, isobutyl, tert-butyl n-pentyl, n-hexyl, n-heptyl, n-octyl. In particular, alkyl relates to a group having 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11 or 12 carbon atoms. The term alkyl also encompasses cycloalkyl radicals including but not limited to cyclopropyl, cyclobutyl, CH2-cyclopropyl, CH2-cyclobutyl, cyclopentyl or cyclohexyl. In particular, cycloalkyl relates to a group having 3, 4, 5, 6, 7, 8, 9, 10, 11 or 12 carbon atoms. Cycloalkyl groups may be optionally substituted or fused to one or more carbocyclyl or heterocyclyl group. Haloalkyl relates to an alkyl radical as defined above preferably having 1 to 8 carbon atoms, preferably 1 to 4 carbon atoms substituted with one or more halide atoms for example one or more of F, Cl, Br or I, such as CH2CH2Br, CF3 or CCl3.
[0105] The term “alkenyl” means a straight chain or branched alkylenyl radical of 2 to 12 carbon atoms, preferably 2 to 6 carbon atoms and most preferably 2 to 4 carbon atoms, and containing one or more carbon-carbon double bonds and includes but is not limited to ethylene, n-propyl-1-ene, n-propyl-2-ene, isopropylene, etc. In particular, alkenyl relates to a group having 2, 3, 4, 5, 6, 7, 8, 9, 10, 11 or 12 carbon atoms. The term “alkynyl” means a straight chain or branched alkynyl radical of 2 to 12 carbon atoms, preferably 2 to 6 carbon atoms and most preferably 2 to 4 carbon atoms, and containing one or more carbon-carbon triple bonds and includes but is not limited to ethynyl, 2-methylethynyl etc. In particular, alkynyl relates to a group having 2, 3, 4, 5, 6, 7, 8, 9, 10, 11 or 12 carbon atoms.
[0106] “Carbocyclyl” relates to a saturated, partly unsaturated or unsaturated 3-12 membered hydrocarbon ring preferably a 6-12 membered hydrocarbon ring, including cycloalkyl and aryl.
[0107] “Aryl” means an aromatic 3-12 membered hydrocarbon preferably a 6-12 membered hydrocarbon containing one ring or being fused to one or more saturated or unsaturated rings including but not limited to phenyl, napthyl, anthracenyl or phenanthracenyl.
[0108] “Heteroaryl” means an aromatic 3-12 membered aryl preferably a 6-12 membered aryl containing one or more heteroatoms selected from N, O or S and containing one ring or being fused to one or more saturated or unsaturated rings and;
[0109] “Heterocyclyl” means a 3-12 membered ring system preferably a 6-12 membered ring system containing one or more heteroatoms selected from N, O or S and includes heteroaryl. In particular the terms “carbocyclyl”, “aryl”, “heteroaryl” and “heterocyclyl” relate to a group having 3, 4, 5, 6, 7, 8, 9, 10, 11 or 12 carbon atoms.
[0110] The heterocyclyl system can contain one ring or may be fused to one or more saturated or unsaturated rings; the heterocyclyl can be fully saturated, partially saturated or unsaturated and includes but is not limited to heteroaryl and heterocarbocyclyl. Examples of carbocyclyl or heterocyclyl groups include but are not limited to cyclohexyl, phenyl, acridine, benzimidazole, benzofuran, benzothiophene, benzoxazole, benzothiazole, carbazole, cinnoline, dioxin, dioxane, dioxolane, dithiane, dithiazine, dithiazole, dithiolane, furan, imidazole, imidazoline, imidazolidine, indole, indoline, indolizine, indazole, isoindole, isoquinoline, isoxazole, isothiazole, morpholine, napthyridine, oxazole, oxadiazole, oxathiazole, oxathiazolidine, oxazine, oxadiazine, phenazine, phenothiazine, phenoxazine, phthalazine, piperazine, piperidine, pteridine, purine, pyran, pyrazine, pyrazole, pyrazoline, pyrazolidine, pyridazine, pyridine, pyrimidine, pyrrole, pyrrolidine, pyrroline, quinoline, quinoxaline, quinazoline, quinolizine, tetrahydrofuran, tetrazine, tetrazole, thiophene, thiadiazine, thiadiazole, thiatriazole, thiazine, thiazole, thiomorpholine, thianaphthalene, thiopyran, triazine, triazole, and trithiane.
[0111] For the purpose of the present invention, the term “fused” includes a polycyclic compound in which one ring contains one or more atoms preferably one, two or three atoms in common with one or more other ring.
[0112] Halogen means F, Cl, Br or I, preferably F.
[0113] Compounds of formula (VII) can be converted into alternative compounds of formula (VII) by conventional methods known in the art. In particular, a compound of formula (VII) may undergo oxidation, reduction, addition, elimination, substitution or transmetallation reactions in order to produce a further compound of formula (VII).
[0114] The compounds of formula (VII) can be aromatised to 5-substituted 7-azaindoles (IX) using methods known in the art, in particular Mn(OAc)3/AcOH or MnO2.
[0115]  [see pdf for image]
[0116] If the compounds of formula (IX) or derivatives thereof (for example compounds of formula (IX) wherein X is hydrogen) are produced for use in medicine, an alternative method to aromatise compounds of formula (VII) is preferred.
[0117] The tenth aspect of the invention provides a method of producing a compound of formula (XI) by the aromatisation of a compound of formula (X) with DDQ wherein efficient oxidation of derivative (X) with DDQ to afford (XI) is promoted by the presence of electron-donating N-silyl group at nitrogen in (X).
[0118]  [see pdf for image]
[0119] wherein X′ is a silyl group (R1)3Si
[0120] R1 is as defined in the first aspect
[0121] X″ is Br or R8
[0122] and R8 is as defined in the ninth aspect
[0123] Preferably X′ is t-butyldimethylsilyl (TBS), triisopropylsilyl (TIPS) or t-butyldimethylphenylsilyl (TBDPS).
[0124] As previously discussed, previous attempts in the art to rearomatise unprotected 7-azaindolines with DDQ resulted in undesirably low yields. The method set out in the tenth aspect of the inveniton utilises the presence of the electron-donating N-silyl group to promote efficient oxidation of (X) with DDQ.
[0125] This method allows the production of 5-substituted-7-azaindole moieties without the need for a high excess of oxidant and avoids the contamination of the product with heavy metal impurities (as can be seen for example with a MnO2 or Mn(OAc)3/AcOH medicated oxidation).
[0126] Removal of the group X′ can be carried out using method known in the art. Suitable methods for removing specific X′ groups are set out in Greene and Wuts Protective Groups in Organic Synthesis, 3rd Edition, Wiley, New York, 1999. For example when X′ is TBS, it can be removed by incubation with hydrochloric acid. Alternatively, when X′ is PhSO2, removal can be afforded with KOH in EtOH.
[0127] The eleventh aspect of the invention provides a compound of formula (XII)
[0128]  [see pdf for image]
wherein R5 is OH or a group OR20 wherein R20 is C1-6 alkyl or C6-12 aryl and wherein two or more R20 groups may together form a 4 to 7 membered ring, and wherein X is a amino-protecting group, preferably selected from R1S(O)2, (R1)3Si, R1C(O), R1OCH2, R12NSO2, R1OC(O)—, R1(R1O)CH—, R1CH2CH2—, R1CH2—, PhC(O)CH2—, CH2═CH—, ClCH2CH2—, Ph3C—, Ph2(4-pyridyl)C—, Me2N—, HO—CH2—, R1OCH2—, (R1)3SiOCH2—, (R1O)2CH—, t-BuOC(O)CH2—, Me2NCH2— and tetrahydropyranylamine;
[0129] wherein R1 is C1-6 alkyl, C3-12 cycloalkyl, C1-6 haloalkyl, C6-12 heterocyclyl or C6-12 carbocyclyl; optionally substituted with one or more of C1-6alkyl, Si(R3)3, OR3, NO2, CO2, CO2R3, halogen, haloalkyl, SR3, CN, NR3COR3, COR13CONR3R3,
[0130] wherein R3 is hydrogen or C1-6 alkyl, preferably R1 is methyl, ethyl, propyl, n-butyl, tert-butyl or phenyl.
[0131] The twelfth aspect of the invention provides a method of producing a compound of formula (XII)
[0132]  [see pdf for image]
comprising incubating a compound of formula (XIII) with (R5)3B and a base wherein R5 is OH, C1-6 alkoxy or C6-12 aryloxy. Preferably, (R5)3B is selected from B(OR15)3 wherein R15 is alkyl, cycloalkyl or two R15 groups may together form a 4 to 7 membered ring
[0133] wherein X is a amino-protecting group, preferably selected from R1S(O)2, (R1)3Si, R1C(O), R1OCH2, R12NSO2, R1OC(O)—, R1(R1O)CH—, R1CH2CH2—, R1CH2—, PhC(O)CH2—, CH2═CH—, ClCH2CH2—, Ph3C—, Ph2(4-pyridyl)C—, Me2N—, HO—CH2—, R1OCH2—, (R1)3SiOCH2—, (R1O)2CH—, t-BuOC(O)CH2—, Me2NCH2— and tetrahydropyranylamine;
[0134] wherein R1 is C1-6 alkyl, C3-12 cycloalkyl, C1-6 haloalkyl, C6-12 heterocyclyl or C6-12 carbocyclyl; optionally substituted with one or more of C1-6 alkyl, Si(R3)3, OR3, NO2, CO2, CO2R3, halogen, haloalkyl, SR3, CN, NR3COR3, COR13CONR3R3,
[0135] wherein R3 is hydrogen or C1-6 alkyl, preferably R1 is methyl, ethyl, propyl, n-butyl, tert-butyl or phenyl.
[0136] The thirteenth aspect of the invention provides a method for the production of a compound of formula (IX)
[0137]  [see pdf for image]
comprising reacting a compound of formula (XII) with R7-Z in the presence of a palladium catalyst.
[0138] wherein R8 is an optionally substituted C1-12 alkyl, C2-12 alkenyl, COR9 carbocyclyl or heterocyclyl group;
[0139] wherein R9 is optionally substituted alkyl, carbocyclyl or heterocyclyl; and
[0140] wherein, each substitutable carbon atom in R8 or R9 is optionally and independently substituted by one or more of C1-12 alkyl, C2-12 alkenyl, carbocyclyl, or heterocyclyl, halogen, haloalkyl, OR10, SR10, NO2, CN, NR10R10, NR10COR10, NR10CONR10R10, NR10COR10, NR10CO2R10, CO2R10, COR10, CONR10R10, S(O)2R10, SONH2, S(O)R10, SO2NR10R10, NR10S(O)2R10, wherein each R10 may be the same or different and is as defined below; wherein the C1-12 alkyl optionally incorporates one or two insertions selected from the group consisting of —O—, —C(O)—, —N(R10)—, —S(O)— and —S(O2)— and wherein the C1-12 alkyl, carbocyclyl, or heterocyclyl group is optionally substituted by one or more of halogen, haloalkyl, OR10, SR, NO2, CN, NR10R10, NR10COR10, NR10CONR10R10, NR10COR10, NR10CO2R10, CO2R10, COR10, CONR102, S(O)2R10, SONH2, S(O)R10, or NR10S(O)2R10;
[0141] each substitutable nitrogen atom in R8 is optionally substituted by R11, COR10, SO2R10 or CO2R10, wherein each R10 and R11 may be the same or different and is as defined below;
[0142] the optionally substituted carbocyclyl or optionally substituted heterocyclyl group is optionally fused to an unsaturated, partially unsaturated or fully saturated five to seven membered ring containing zero to three heteroatoms, each saturated carbon in the optional fused ring is further optionally and independently substituted by ═O, ═S, ═NNHR10, NNR10R10, ═N—OR10, ═NNHCOR10, ═NNHCO2R10, ═NNSO2R10, or ═NR10, wherein each R10 may be the same or different and is as defined below;
[0143] R10 is hydrogen, C1-12 alkyl or aryl, optionally substituted by one or more of C1-4 alkyl, halogen, C1-4 haloalkyl, OR12, SR12, NO2, CN, NR12R12, NR12COR12, NR12CONR12R12, NR12COR12, NR12CO2R12, CO2R12, COR12, CONR122, S(O)2R12, SONH2, S(O)R12, SO2NR12R12, NR12S(O)2R12, wherein the C1-12 alkyl group optionally incorporates one or two insertions selected from the group consisting of —O—, —N(R12)—, —S(O)— and —S(O2)—, wherein each R12 may be the same or different and is as defined below;
[0144] R11 is C1-12 alkyl or aryl, optionally substituted by one or more of C1-4 alkyl, halogen, C1-4 haloalkyl, OR12, SR12, NO2, CN, NR12R12, NR12COR12, NR12CONR12R12, NR12COR12, NR12CO2R12, CO2R12, COR12, CONR122, S(O)2R12, SONH2, S(O)R12, SO2 NR12R12, NR12S(O)2R12, wherein the C1-12 alkyl group optionally incorporates one or two insertions selected from the group consisting of —O—, —N(R12)—, —S(O)— and —S(O2)—, wherein each R12 may be the same or different and is as defined below;
[0145] R12 is hydrogen, C1-4 alkyl, or C1-4 haloalkyl;
[0146] wherein X is a amino-protecting group, preferably selected from R1S(O)2, (R1)3Si, R1C(O), R1OCH2, R12NSO2, R1OC(O)—, R1(R1O)CH—, R1CH2CH2—, R1CH2—, PhC(O)CH2—, CH2═CH—, ClCH2CH2—, Ph3C—, Ph2(4-pyridyl)C—, Me2N—, HO—CH2—, R1OCH2—, (R1)3SiOCH2—, (R1O)2CH—, t-BuOC(O)CH2—, Me2NCH2— and tetrahydropyranylamine;
[0147] wherein R1 is C1-6 alkyl, C3-12 cycloalkyl, C1-6 haloalkyl, C6-12 heterocyclyl or C6-12 carbocyclyl; optionally substituted with one or more of C1-6 alkyl, Si(R3)3, OR3, NO2, CO2, CO2R3, halogen, haloalkyl, SR3, CN, NR3COR3, COR13CONR3R3,
[0148] wherein R3 is hydrogen or C1-6 alkyl, preferably R1 is methyl, ethyl, propyl, n-butyl, tert-butyl or phenyl.
[0149] wherein R7 is independently selected from an optionally substituted C1-12 alkyl, C2-12 alkenyl, COR9, carbocyclyl or heterocyclyl group and Z is a halogen or triflate preferably iodine, bromine or chlorine.
[0150] It will be appreciated that the reaction set out is a Suzuki reaction which can be carried out according to Suzuki Pure Appl. Chem., 1991, 63, 419, or Littke J. Am. Chem. Soc. 2000, 122, 4020.
[0151] The fourteenth aspect of the invention provides a compound of formula (XIV)
[0152]  [see pdf for image]
wherein R4 is a C1-6alkyl, OH, or an C6-12 aryl group, X is an amino-protecting group, preferably selected from R1S(O)2, (R1)3Si, R1C(O), R1OCH2, R12NSO2, R1OC(O)—, R1(R1O)CH—, R1CH2CH2—, R1CH2—, PhC(O)CH2—, CH2═CH—, ClCH2CH2—, Ph3C—, Ph2(4-pyridyl)C—, Me2N—, HO—CH2—, R1OCH2—, (R1)3SiOCH2—, (R1O)2CH—, t-BuOC(O)CH2—, Me2NCH2— and tetrahydropyranylamine;
[0153] wherein R1 is C1-6 alkyl, C3-12 cycloalkyl, C1-6 haloalkyl, C6-12 heterocyclyl or C6-12 carbocyclyl; optionally substituted with one or more of C1-6 alkyl, Si(R3)3, OR3, NO2, CO2, CO2R3, halogen, haloalkyl, SR3, CN, NR3COR3, COR13CONR3R3,
[0154] wherein R3 is hydrogen or C1-6 alkyl, preferably R1 is methyl, ethyl, propyl, n-butyl, tert-butyl or phenyl.
[0155] The fifteenth aspect of the invention provides a method for the production of compound of formula (IX)
[0156]  [see pdf for image]
[0157] comprising reacting a compound of formula (XII) with R7-Z in the presence of a palladium catalyst
[0158] wherein R8 is an optionally substituted C1-12 alkyl, C2-12 alkenyl, COR9 carbocyclyl or heterocyclyl group;
[0159] wherein R9 is optionally substituted alkyl, carbocyclyl or heterocyclyl; and
[0160] wherein, each substitutable carbon atom in R8 or R9 is optionally and independently substituted by one or more of C1-12 alkyl, C2-12 alkenyl, carbocyclyl, or heterocyclyl, halogen, haloalkyl, OR10, SR10, NO2, CN, NR10R10, NR10COR10 , NR10CONR10R10, NR10COR10, NR10CO2R10, CO2R10, COR10, CONR10R10, S(O)2R10, SONH2, S(O)R10, SO2NR10R10, NR10S(O)2R10, wherein each R10 may be the same or different and is as defined below; wherein: the C1-12 alkyl optionally incorporates one or two insertions selected from the group consisting of —O—, —C(O)—, —N(R10)—, —S(O)— and —S(O2)— and wherein the C1-12 alkyl, carbocyclyl, or heterocyclyl group is optionally substituted by one or more of halogen, haloalkyl, OR10, SR, NO2, CN, NR10R10, NR10COR10, NR10CONR10R10, NR10COR10, NR10CO2R10, CO2R10, COR10, CONR102, S(O)2R10, SONH2, S(O)R10, or NR10S(O)2R10;
[0161] each substitutable nitrogen atom in R8 is optionally substituted by R11, COR10, SO2R10 or CO2R10, wherein each R10 and R11 may be the same or different and is as defined below;
[0162] the optionally substituted carbocyclyl or optionally substituted heterocyclyl group is optionally fused to an unsaturated, partially unsaturated or fully saturated five to seven membered ring containing zero to three heteroatoms, each saturated carbon in the optional fused ring is further optionally and independently substituted by ═O, ═S, ═NNHR10, NNR10R10, ═N—OR10, ═NNHCOR10, ═NNHCO2R10, ═NNSO2R10, or ═NR10, wherein each R10 may be the same or different and is as defined below;
[0163] R10 is hydrogen, C1-12 alkyl or aryl, optionally substituted by one or more of C1-4 alkyl, halogen, C1-4 haloalkyl, OR12, SR12, NO2, CN, NR12R12, NR12COR12, NR12CONR12R12, NR12COR12, NR12CO2R12, CO2R12, COR12, CONR122, S(O)2R12, SONH2, S(O)R12, SO2NR12R12, NR12S(O)2R12, wherein the C1-12 alkyl group optionally incorporates one or two insertions selected from the group consisting of —O—, —N(R12)—, —S(O)— and —S(O2)—, wherein each R12 may be the same or different and is as defined below;
[0164] R11 is C1-12 alkyl or aryl, optionally substituted by one or more of C1-4 alkyl, halogen, C1-4 haloalkyl, OR12, SR12, NO2, CN, NR12R12, NR12COR12, NR12CONR12R12, NR12COR12, NR12CO2R12, CO2R12, COR12, CONR122, S(O)2R12, SONH2, S(O)R12, SO2 NR12R12, NR12S(O)2R12, wherein the C1-12 alkyl group optionally incorporates one or two insertions selected from the group consisting of —O—, —N(R12)—, —S(O)— and —S(O2)—, wherein each R12 may be the same or different and is as defined below;
[0165] R12 is hydrogen, C1-4 alkyl, or C1-4 haloalkyl;
[0166] wherein X is a amino-protecting group, preferably selected from R1S(O)2, (R1)3Si, R1C(O), R1OCH2, R12NSO2, R1OC(O)—, R1(R1O)CH—, R1CH2CH2—, R1CH2—, PhC(O)CH2—, CH2═CH—, ClCH2CH2—, Ph3C—, Ph2(4-pyridyl)C—, Me2N—, HO—CH2—, R1OCH2—, (R1)3SiOCH2—, (R1O)2CH—, t-BuOC(O)CH2—, Me2NCH2— and tetrahydropyranylamine;
[0167] wherein R1 is C1-6 alkyl, C3-12 cycloalkyl, C1-6 haloalkyl, C6-12 heterocyclyl or C6-12 carbocyclyl; optionally substituted with one or more of C1-6 alkyl, Si(R3)3, OR3, NO2, CO2, CO2R3, halogen, haloalkyl, SR3, CN, NR3COR3, COR13CONR3R3,
[0168] wherein R3 is hydrogen or C1-6 alkyl, preferably R1 is methyl, ethyl, propyl, n-butyl, tert-butyl or phenyl.
[0169] wherein R7 is independently selected from an optionally substituted C1-12 alkyl, C2-12 alkenyl, COR9, carbocyclyl or heterocyclyl group and Z is a halogen or triflate preferably iodide, bromide or chloride.
[0170] It will be appreciated that the reaction set out is a Hiyama reaction which can be carried out according to Hatanaka et al. J. Org. Chem. 1988, 53, 918, Hatanaka et al. Synlett 1991, 845 or Tamao et al. Tetrahedron Lett. 1989, 30, 6051, or Denmark et al. Org. Lett. 2000, 2, 565, ibid. 2491.
[0171] The sixteenth aspect of the invention provides a method of producing 7-azaindoline from 7-azaindole, comprising the reaction of 7-azaindole with a formic acid-triethylamine mixture in the presence of a palladium catalyst, followed by incubation with sodium hydroxide.
[0172]  [see pdf for image]
[0173] This method avoids using high pressure, gaseous hydrogen, avoids concomitant formation of overreduced products and occurs at relatively low temperature.
[0174] The seventeenth aspect provides a compound of formula (XV)
[0175]  [see pdf for image]
wherein R8 is as defined in the ninth aspect
[0176] In a preferred feature R8 is substituted aryl, preferably substituted phenyl or optionally substituted five-membered heterocyclyl or aryl-C(O).
[0177] The eighteenth aspect provides a method for the production of a compound of formula (XV)
[0178]  [see pdf for image]
comprising a) a reaction of a compound of formula (III) with R8—B(OR15)2 in the presence of a palladium catalyst
[0179]  [see pdf for image]
b) reacting a compound of formula (III) with R8—Sn(R2)3 in the presence of a palladium catalyst c) reacting a compound of formula (III) with R8—Si(R4)3 in the presence of a fluoride and a palladium catalyst;
[0180] wherein R8 is as defined in the ninth aspect
[0181] In a preferred feature R8 is substituted aryl, preferably substituted phenyl or optionally substituted five-membered heterocyclyl;
[0182] wherein R15 is hydrogen, C1-6 alkyl or C6-12 aryl and wherein two or more R15 groups may together form a 4 to 7 membered ring;
[0183] In a preferred feature R15 is hydrogen, —CMe2CMe2—, methyl, ethyl.
[0184] wherein R2 is as defined in the third aspect
[0185] R4 is as define d in the fifth aspect
[0186] In a preferred feature R2 is C1-4 alkyl, most preferably methyl, ethyl, propyl and butyl.
[0187] For the avoidance of doubt, when a group as defined above contains two or more radicals, e.g. the radical R4, as for example in SiR4R4, the two or more radicals e.g. R4 may be the same or different.
[0188] It will be appreciated that the reaction set out in option a) for the eighteenth aspect is a Suzuki coupling reaction which can be carried out according to Suzuki Pure Appl. Chem. 1991, 63, 419; and Martin and Yang Acta Chem. Scand. 1993, 47, 221, or Littke J. Am. Chem. Soc. 2000, 122, 4020.
[0189] It will be appreciated that the reaction set out in option b) for the eighteenth aspect is a Stille coupling reaction which can be carried out according to Stille Angew. Chem. Int. Ed. 1986, 25, 508; Mitchell, Synthesis 1992, 803, or Littke et al. J. Am. Chem. Soc. 2002, 124, 6343.
[0190] It will be appreciated that the reaction set out in option c) for the eighteenth aspect is a Hiyama coupling reaction which can be carried out according to Hatanaka and Hiyama J. Org. Chem. 1988, 53, 918; Hatanaka and Hiyama Synlett. 1991, 845; Tamao et al. Tetrahedron Lett. 1989, 30, 6051, or Denmark et al. Org. Lett. 2000, 2, 565, ibid. 2491.
[0191] In a preferred feature of the eighteenth aspect a compound of formula (III) is incubated with an aryl boronic acid R8—B(OH)2, heteroaryl boronic acid R8—B(OH)2, aryltrialkyl stannane R8—Sn(R2)3, or heteroaryltrialkylstannane R8—Sn(R2)3 where R8 is as defined above and R2 is C1-4 alkyl.
[0192] Compound (III) is formed by bromination of 7-azaindoline according to methods known in the art.
[0193] The nineteenth aspect provides a method for the production of a compound of formula (VII)
[0194]  [see pdf for image]
comprising a) a reaction of a compound of formula (I) with R8—B(OR15)2 in the presence of a palladium catalyst;
[0195]  [see pdf for image]
b) reacting a compound of formula (I) with R8—Sn(R2)3 in the presence of a palladium catalyst or c) reacting a compound of formula (I) with R8—Si(R4)3 in the presence of a fluoride and a palladium catalyst;
[0196] wherein R8 is as defined in the ninth aspect
[0197] In a preferred feature R8 is substituted aryl, preferably substituted phenyl or optionally substituted five-membered heterocyclyl;
[0198] wherein X is an amino-protecting group as defined in the first aspect, preferably selected from R1S(O)2, (R1)3Si, R1C(O), R1OCH2, R12NSO2, R1OC(O)—, R1(R1O)CH—, R1CH2CH2—, R1CH2—, PhC(O)CH2—, CH2═CH—, ClCH2CH2—, Ph3C—, Ph2(4-pyridyl)C—, Me2N—, HO—CH2—, R1OCH2—, (R1)3SiOCH2—, (R1O)2CH—, t-BuOC(O)CH2—, Me2NCH2— and tetrahydropyranylamine;
[0199] wherein R1 is C1-6 alkyl, C3-12 cycloalkyl, C1-6 haloalkyl, C6-12 heterocyclyl or C6-12 carbocyclyl; optionally substituted with one or more of C1-6 alkyl, Si(R3)3, OR3, NO2, CO2, CO2R3, halogen, haloalkyl, SR3, CN, NR3COR3, COR13CONR3R3,
[0200] wherein R3 is hydrogen or C1-6 alkyl, preferably R1 is methyl, ethyl, propyl, n-butyl, tert-butyl or phenyl.
[0201] wherein R15 is hydrogen, C1-6 alkyl or C6-12 aryl and wherein two or more R15 groups may together form a 4 to 7 membered ring;
[0202] In a preferred feature R15 is hydrogen, —CMe2CMe2—, methyl, ethyl.
[0203] wherein R2 is as defined in the third aspect
[0204] In a preferred feature R2 is C1-4 alkyl, most preferably methyl, ethyl, propyl and butyl.
[0205] R4 is as defined in the fifth aspect
[0206] For the avoidance of doubt, when a group as defined above contains two or more radicals, e.g. the radical R1, as for example in NR1R1, the two or more radicals e.g. R1 may be the same or different.
[0207] It will be appreciated that the reaction set out in option a) for the nineteenth aspect is a Suzuki coupling reaction which can be carried out according to Suzuki Pure Appl. Chem. 1991, 63, 419; and Martin and Yang Acta Chem. Scand. 1993, 47, 221, or Littke J. Am. Chem. Soc. 2000, 122, 4020.
[0208] It will be appreciated that the reaction set out in option b) for the nineteenth aspect is a Stille coupling reaction which can be carried out according to Stille Angew. Chem. Int. Ed. 1986 25, 508; Mitchell, Synthesis 1992, 803, or Littke et al. J. Am. Chem. Soc. 2002, 124, 6343.
[0209] It will be appreciated that the reaction set out in option c) for the nineteenth aspect is a Hiyama coupling reaction which can be carried out according to Hatanaka and Hiyama J. Org. Chem. 1988, 53, 918; Hatanaka and Hiyama Synlett. 1991, 845; Tamao et al. Tetrahedron Lett. 1989, 30, 6051, or Denmark et al. Org. Lett. 2000, 2, 565, ibid. 2491.
[0210] In a preferred feature of the nineteenth aspect a compound of formula (I) is incubated with an aryl boronic acid R8—B(OH)2, heteroaryl boronic acid R8—B(OH)2, aryltrialkyl stannane R8—Sn(R2)3, or heteroaryltrialkylstannane R8—Sn(R2)3 where R8 is as defined above and R2 is C1-4 alkyl.
[0211] The twentieth aspect provides a compound of formula (XIII)
[0212]  [see pdf for image]
wherein X is an amino-protecting group as defined in the first aspect, preferably selected from R1S(O)2, (R1)3Si, R1C(O), R1OCH2, R12NSO2, R1OC(O)—, R1(R1O)CH—, R1CH2CH2—, R1CH2—, PhC(O)CH2—, CH2═CH—, ClCH2CH2—, Ph3C—, Ph2(4-pyridyl)C—, Me2N—, HO—CH2—, R1OCH2—, (R1)3SiOCH2—, (R1O)2CH—, t-BuOC(O)CH2—, Me2NCH2— and tetrahydropyranylamine;
[0213] wherein R1 is C1-6 alkyl, C3-12 cycloalkyl, C1-6 haloalkyl, C6-12 heterocyclyl or C6-12 carbocyclyl; optionally substituted with one or more of C1-6 alkyl, Si(R3)3, OR3, NO2, CO2, CO2R3, halogen, haloalkyl, SR3, CN, NR3COR3, COR13CONR3R3,
[0214] wherein R3 is hydrogen or C1-6 alkyl, preferably R1 is methyl, ethyl, propyl, n-butyl, tert-butyl or phenyl.
[0215] The twenty first aspect provides a method for the production of a compound of formula (XVI)
[0216]  [see pdf for image]
comprising a) a reaction of a compound of formula (XVII) with R8—B(OR15)2 in the presence of a palladium catalyst; or
[0217]  [see pdf for image]
b) reacting a compound of formula (XVII) with R8—Sn(R2)3 in the presence of a palladium catalyst c) reacting a compound of formula (XVII) with R8—Si(R4)3 in the presence of a fluoride and a palladium catalyst;
[0218] wherein R8 is as defined in the ninth aspect
[0219] In a preferred feature R8 is substituted aryl, preferably substituted phenyl or optionally substituted five-membered heterocyclyl;
[0220] wherein R2 is as defined in the third aspect
[0221] In a preferred feature R2 is C1-4 alkyl, most preferably methyl, ethyl, propyl and butyl.
[0222] wherein R4 is as defined in the fifth aspect
[0223] wherein R15 is as defined in the seventh aspect
[0224] In a preferred feature R15 is hydrogen, —CMe2CMe2—, methyl, ethyl.
[0225] For the avoidance of doubt, when a group as defined above contains two or more radicals, e.g. the radical R2, as for example in SnR2R2, the two or more radicals e.g. R2 may be the same or different.
[0226] It will be appreciated that the reaction set out in option a) for the twenty first aspect is a Suzuki coupling reaction which can be carried out according to Suzuki Pure Appl. Chem. 1991, 63, 419; and Martin and Yang Acta Chem. Scand. 1993, 47, 221, or Littke J. Am. Chem. Soc. 2000, 122, 4020.
[0227] It will be appreciated that the reaction set out in option b) for the twenty first aspect is a Stille coupling reaction which can be carried out according to Stille Angew. Chem. Int. Ed. 1986, 25, 508; Mitchell, Synthesis 1992, 803, or Littke et al. J. Am. Chem. Soc. 2002, 124, 6343.
[0228] It will be appreciated that the reaction set out in option c) for the twenty first aspect is a Hiyama coupling reaction which can be carried out according to Hatanaka and Hiyama J. Org. Chem. 1988, 53, 918; Hatanaka and Hiyama Synlett. 1991, 845; Tamao et al. Tetrahedron Lett. 1989, 30, 6051, or Denmark et al. Org. Lett. 2000, 2, 565, ibid. 2491.
[0229] In a preferred feature of the twenty first aspect a compound of formula (I) is incubated with an aryl boronic acid R8—B(OH)2, heteroaryl boronic acid R8—B(OH)2, aryltrialkyl stannane R8—Sn(R2)3, or heteroaryltrialkylstannane R8—Sn(R2)3 where R8 is as defined above and R2 is C1-4 alkyl.
[0230] The twenty-second aspect provides a method for the production of a compound of formula (IX)
[0231]  [see pdf for image]
comprising a) a reaction of a compound of formula (XIII) with R8—B(OR15)2 in the presence of a palladium catalyst; or
[0232]  [see pdf for image]
b) reacting a compound of formula (XIII) with R8—Sn(R2)3 in the presence of a palladium catalyst c) reacting a compound of formula (XIII) with R8—Si(R4)3 in the presence of a fluoride and a palladium catalyst;
[0233] wherein R2 is as defined in the third aspect
[0234] wherein R4 is as defined in the fifth aspect
[0235] wherein R8 is as defined in the ninth aspect
[0236] In a preferred feature R8 is substituted aryl, preferably substituted phenyl or optionally substituted five-membered heterocyclyl;
[0237] wherein X is an amino-protecting group as defined in the first aspect of the invention, preferably selected from R1S(O)2, (R1)3Si, R1C(O), R1OCH2, R12NSO2, R1OC(O)—, R1(R1O)CH—, R1CH2CH2—, R1CH2—, PhC(O)CH2—, CH2═CH—, ClCH2CH2—, Ph3C—, Ph2(4-pyridyl)C—, Me2N—, HO—CH2—, R1OCH2—, (R1)3SiOCH2—, (R1O)2CH—, t-BuOC(O)CH2—, Me2NCH2— and tetrahydropyranylamine;
[0238] wherein R1 is C1-6 alkyl, C3-12 cycloalkyl, C1-6 haloalkyl, C6-12 heterocyclyl or C6-12 carbocyclyl; optionally substituted with one or more of C1-6 alkyl, Si(R3)3, OR3, NO2, CO2, CO2R3, halogen, haloalkyl, SR3, CN, NR3COR3, COR13CONR3R3,
[0239] wherein R3 is hydrogen or C1-6 alkyl, preferably R1 is methyl, ethyl, propyl, n-butyl, tert-butyl or phenyl.
[0240] wherein R15 is as defined in the seventh aspect
[0241] In a preferred feature R15 is hydrogen, —CMe2CMe2—, methyl, ethyl.
[0242] In a preferred feature R2 is C1-4 alkyl, most preferably methyl, ethyl, propyl and butyl.
[0243] R4 is hydrogen, C1-4 alkyl, or C1-4 haloalkyl;
[0244] For the avoidance of doubt, when a group as defined above contains two or more radicals, e.g. the radical R2, as for example in SnR2R2, the two or more radicals e.g. R2 may be the same or different.
[0245] It will be appreciated that the reaction set out in option a) for the twenty-second aspect is a Suzuki coupling reaction which can be carried out according to Suzuki Pure Appl. Chem. 1991, 63, 419; and Martin and Yang Acta Chem. Scand. 1993, 47, 221, or Littke J. Am. Chem. Soc. 2000, 122, 4020.
[0246] It will be appreciated that the reaction set out in option b) for the twenty-second aspect is a Stille coupling reaction which can be carried out according to Stille Angew. Chem. Int. Ed. 1986, 25, 508; Mitchell, Synthesis 1992, 803, or Littke et al. J. Am. Chem. Soc. 2002, 124, 6343.
[0247] It will be appreciated that the reaction set out in option c) for the twenty-second aspect is a Hiyama coupling reaction which can be carried out according to Hatanaka and Hiyama J. Org. Chem. 1988, 53, 918; Hatanaka and Hiyama Synlett. 1991, 845; Tamao et al. Tetrahedron Lett. 1989, 30, 6051, or Denmark et al. Org. Lett. 2000, 2, 565, ibid. 2491.
[0248] In a preferred feature of the twenty-second aspect a compound of formula (I) is incubated with an aryl boronic acid R8—B(OH)2, heteroaryl boronic acid R8—B(OH)2, aryltrialkyl stannane R8—Sn(R2)3, or heteroaryltrialkylstannane R8—Sn(R2)3 where R8 is as defined above and R2 is C1-4 alkyl.
[0249] The twenty third aspect of the invention provides an alternative method for the production of a compound of formula (IX)
[0250]  [see pdf for image]
comprising a reaction of a compound of formula (XVIII) with R6-Z in the presence of a palladium catalyst
[0251]  [see pdf for image]
wherein R2 is as defined in the third aspect
[0252] wherein R6 and R8 are as defined in the ninth aspect
[0253] wherein Z is defined in the fifth aspect
[0254] wherein X is an amino-protecting group as defined in the first aspect, preferably selected from R1S(O)2, (R1)3Si, R1C(O), R1OCH2, R12NSO2, R1OC(O)—, R1(R1O)CH—, R1CH2CH2—, R1CH2—, PhC(O)CH2—, CH2═CH—, ClCH2CH2—, Ph3C—, Ph2(4-pyridyl)C—, Me2N—, HO—CH2—, R1OCH2—, (R1)3SiOCH2—, (R1O)2CH—, t-BuOC(O)CH2—, Me2NCH2— and tetrahydropyranylamine;
[0255] wherein R1 is C1-6 alkyl, C3-12 cycloalkyl, C1-6 haloalkyl, C6-12 heterocyclyl or C6-12 carbocyclyl; optionally substituted with one or more of C1-6 alkyl, Si(R3)3, OR3, NO2, CO2, CO2R3, halogen, haloalkyl, SR3, CN, NR3COR3, COR13CONR3R3,
[0256] wherein R3 is hydrogen or C1-6 alkyl, preferably R1 is methyl, ethyl, propyl, n-butyl, tert-butyl or phenyl.
[0257] It will be appreciated that the reaction set out in the twenty third aspect is a Stille coupling reaction which can be carried out according to Stille Angew. Chem. Int. Ed. 1986, 25, 508; Mitchell, Synthesis 1992, 803, or Littke et al. J. Am. Chem. Soc. 2002, 124, 6343.
[0258] The twenty fourth aspect provides a compound of formula (XVIII)
[0259]  [see pdf for image]
wherein R2 is as defined in the third aspect
[0260] wherein X is an amino-protecting group as defined in the first aspect, preferably selected from R1S(O)2, (R1)3Si, R1C(O), R1OCH2, R12NSO2, R1OC(O)—, R1(R1O)CH—, R1CH2CH2—, R1CH2—, PhC(O)CH2—, CH2═CH—, ClCH2CH2—, Ph3C—, Ph2(4-pyridyl)C—, Me2N—, HO—CH2—, R1OCH2—, (R1)3SiOCH2—, (R1O)2CH—, t-BuOC(O)CH2—, Me2NCH2— and tetrahydropyranylamine;
[0261] wherein R1 is C1-6 alkyl, C3-12 cycloalkyl, C1-6 haloalkyl, C6-12 heterocyclyl or C6-12 carbocyclyl; optionally substituted with one or more of C1-6 alkyl, Si(R3)3, OR3, NO2, CO2, CO2R3, halogen, haloalkyl, SR3, CN, NR3COR3, COR13CONR3R3,
[0262] wherein R3 is hydrogen or C1-6 alkyl, preferably R1 is methyl, ethyl, propyl, n-butyl, tert-butyl or phenyl.
[0263] The twenty fifth aspect of the invention provides a method of producing a compound of formula (XVIII)
[0264]  [see pdf for image]
comprising incubating a compound of formula (XIII) with a base followed by addition of (R2)3Sn—W
[0265] wherein R2 and W are as defined in the third aspect
[0266] wherein X is an amino-protecting group as defined in the first aspect, preferably selected from R1S(O)2, (R1)3Si, R1C(O), R1OCH2, R12NSO2, R1OC(O)—, R1(R1O)CH—, R1CH2CH2—, R1CH2—, PhC(O)CH2—, CH2═CH—, ClCH2CH2—, Ph3C—, Ph2(4-pyridyl)C—, Me2N—, HO—CH2—, R1OCH2—, (R1)3SiOCH2—, (R1O)2CH—, t-BuOC(O)CH2—, Me2NCH2— and tetrahydropyranylamine;
[0267] wherein R1 is C1-6 alkyl, C3-12 cycloalkyl, C1-6 haloalkyl, C6-12 heterocyclyl or C6-12 carbocyclyl; optionally substituted with one or more of C1-6 alkyl, Si(R3)3, OR3, NO2, CO2, CO2R3, halogen, haloalkyl, SR3, CN, NR3COR3, COR13CONR3R3,
[0268] wherein R3 is hydrogen or C1-6 alkyl, preferably R1 is methyl, ethyl, propyl, n-butyl, tert-butyl or phenyl.
[0269] The twenty sixth aspect provides a compound of formula (VIIa)
[0270]  [see pdf for image]
wherein R9 is as defined in the ninth aspect
[0271] wherein X is an amino-protecting group as defined in the first aspect, preferably selected from R1S(O)2, (R1)3Si, R1C(O), R1OCH2, R12NSO2, R1OC(O)—, R1(R1O)CH—, R1CH2CH2—, R1CH2—, PhC(O)CH2—, CH2═CH—, ClCH2CH2—, Ph3C—, Ph2(4-pyridyl)C—, Me2N—, HO—CH2—, R1OCH2—, (R1)3SiOCH2—, (R1O)2CH—, t-BuOC(O)CH2—, Me2NCH2— and tetrahydropyranylamine;
[0272] wherein R1 is C1-6 alkyl, C3-12 cycloalkyl, C1-6 haloalkyl, C6-12 heterocyclyl or C6-12carbocyclyl; optionally substituted with one or more of C1-6 alkyl, Si(R3)3, OR3, NO2, CO2, CO2R3, halogen, haloalkyl, SR3, CN, NR3COR3, COR13CONR3R3,
[0273] wherein R3 is hydrogen or C1-6 alkyl, preferably R1 is methyl, ethyl, propyl, n-butyl, tert-butyl or phenyl.
[0274] The twenty seventh aspect provides a compound of formula (IXa)
[0275]  [see pdf for image]
wherein R9 is as defined in the ninth aspect
[0276] wherein X is an amino-protecting group as defined in the first aspect, preferably selected from R1S(O)2, (R1)3Si, R1C(O), R1OCH2, R12NSO2, R1OC(O)—, R1(R1O)CH—, R1CH2CH2—, R1CH2—, PhC(O)CH2—, CH2═CH—, ClCH2CH2—, Ph3C—, Ph2(4-pyridyl)C—, Me2N—, HO—CH2—, R1OCH2—, (R1)3SiOCH2—, (R1O)2CH—, t-BuOC(O)CH2—, Me2NCH2— and tetrahydropyranylamine;
[0277] wherein R1 is C1-6 alkyl, C3-12 cycloalkyl, C1-6 haloalkyl, C6-12 heterocyclyl or C6-12 carbocyclyl; optionally substituted with one or more of C1-6 alkyl, Si(R3)3, OR3, NO2, CO2, CO2R3, halogen, haloalkyl, SR3, CN, NR3COR3, COR13CONR3R3,
[0278] wherein R3 is hydrogen or C1-6 alkyl, preferably R1 is methyl, ethyl, propyl, n-butyl, tert-butyl or phenyl.
[0279] The twenty eighth aspect provides a compound of formula (XVIa)
[0280]  [see pdf for image]
wherein R9 is as defined in the ninth aspect
[0281] The present invention encompasses one or more compounds as defined in the first, fourth, fifth, sixth, seventh, ninth, twelfth, thirteenth, fourteenth, fifteenth, sixteenth, eighteenth, twentieth, twenty fourth, twenty sixth, twenty seventh and twenty eighth aspects of the invention and as set out below;
[0282]  [see pdf for image]
[0283] All features of each of the aspects apply to all other aspects mutatis mutandis.
[0284] The invention will now be illustrated by reference to one or more of the following non-limiting examples.

EXPERIMENTAL

Synthesis of N-protected 5-bromo-7-azaindolines 4 and 6

[0285]  [see pdf for image]

2,3-Dihydro-1H-pyrrolo[2,3-b]pyridine (2)

[0286]  [see pdf for image]
[0287] 98% Formic acid (37.5 mL, 0.97 mol) was added to a stirred and cooled (ice bath) neat Et3N (150 mL, 1.08 mol). A two-phase system, which was formed, was then added to a mixture of 7-azaindole (50.0 g, 0.424 mol), formic acid (750 mL), and 10% palladium on activated carbon (26.75 g, Degussa type), and stirred at 80° C. for 4 d. The mixture was cooled to r.t., the catalyst was filtered off and washed with formic acid (100 mL). The filtrate and washings were combined and concentrated in vacuum. The residual liquid was cooled (ice bath) and basified to pH 13 by slow addition of 50% aqueous NaOH (total of about 500 mL). Then, the mixture was refluxed for 2 h until TLC showed completion. Ice was added in amount sufficient to lower the temperature of the mixture to 20° C. The two-phase system was then extracted with AcOEt (5×500 mL). Combined extracts were washed with brine, dried MgSO4, and concentrated in vacuum. The residual brown solid was separated by means of SGC with AcOEt:MeOH as eluent to afford recovered 1 (12.57 g, 25%) and desired 2 (36.05 g, 71%). 1H NMR (400 MHz, CDCl3) δ 3.05 (t, J=8.4 Hz, 2H), 3.60 (t, J=8.4 Hz, 2H), 4.52 (bs, 1H), 6.49 (dd, J=7.0, 5.3 Hz, 1H), 7.23 (dq, J=7.0, 1.3 Hz, 1H), 7.81 (ddt, J=5.3, 1.3, 1.1 Hz, 1H).

1-(tert-Butyl-dimethyl-silanyl)-2,3-dihydro-1H-pyrrolo[2,3-b]pyridine (3)

[0288]  [see pdf for image]
[0289] To a stirred and cooled (0° C.) solution of 7-azaindoline 2 (6.6 g, 54.9 mmol) in N,N-dimethylacetamide (18.5 mL) was added a 60% dispersion of sodium hydride in mineral oil (3.3 g, 82.4 mmol) portionwise. The mixture was stirred for 30 min and a solution of TBSCl (12.41 g, 82.4 mmol) in N,N-dimethylacetamide (25.1 mL) was added dropwise. The mixture was allowed to warm slowly to r.t. Following a further 18 h stirring the mixture was partitioned between AcOEt and saturated brine. The aqueous layer was extracted with AcOEt (2×). The combined organic solutions were washed with brine, dried (MgSO4), filtered and concentrated. The residue was purified by silicagel chromatography (SGC) using hexane:AcOEt as eluent (in gradient) to afford the desired 3 (8.15 g, 63%) as a pale yellow oil. 1H NMR (400 MHz; CDCl3) δ 0.33 (s, 6H), 0.97 (s, 9H), 2.99 (t, J=9.1 Hz, 2H), 3.65 (t, J=9.1 Hz, 2H), 6.38 (d, J=5.2 Hz, 1H), 7.14 (d, J=1.7 Hz, 1H), 7.79 (dd, J=1.7, 5.2 Hz, 1H).

5-Bromo-1-(tert-butyl-dimethyl-silanyl)-2,3-dihydro-1H-pyrrolo[2,3-b]pyridine (4)

[0290]  [see pdf for image]
[0291] To a stirred and cooled (0° C.) solution of the azaindoline 3 (1.1 g, 4.7 mmol) in CH2Cl2 (25 mL) and pyridine (0.46 mL, 5.6 mmol) was added dropwise a solution of bromine (0.24 mL, 4.7 mmol) in CH2Cl2 (15 mL) over a period of 13 min. After a further 20 min stirring the mixture was diluted with a NaHCO3—Na2S2O3 (1:1 v/v) solution and stirred vigorously for 50 min. The resulting mixture was partitioned and the aqueous layer extracted with CH2Cl2 (3×). The combined organic extracts were dried (MgSO4), filtered and concentrated. The residue was purified by SGC with hexane:AcOEt as eluent (in gradient up to 1.3% AcOEt) to afford the bromo derivative 4 (1.13 g, 77%) as a pale yellow oil. 1H NMR (400 MHz; CDCl3) δ 0.31 (s, 6H), 0.95 (s, 9H), 2.99 (t, J=9.1 Hz, 2H), 3.67 (t, J=9.1 Hz, 2H), 7.20 (m, 1H), 7.79 (m, 1H).

5-Bromo-2,3-dihydro-1H-pyrrolo[2,3-b]pyridine (5)

[0292]  [see pdf for image]
[0293] A solution of Br2 (18.1 mL, 56.2 g, 0.351 mol) in dry CH2Cl2 (250 mL) was added dropwise over a period of 1 h 45 min to a stirred and cooled (−5° C.) solution of 2 (42.22 g, 0.351 mol) in dry CH2Cl2 (410 mL)-pyridine (40 mL). The yellow suspension was stirred at 0° C. for 45 min and poured into a mixture of saturated aqueous NaHCO3 (800 mL) and saturated aqueous Na2S2O3 (100 mL). Methanol (10 mL) was added and the lower organic layer was separated and dried over MgSO4. The aqueous layer was extracted with AcOEt:MeOH=99:1 (7×1000 mL). These extracts were also dried with MgSO4. The organic solutions were combined and concentrated to afford 5 (59.17 g, 85%), which was used in the next step without further purification. 1H NMR (400 MHz, CDCl3) δ 3.07 (tt, J=8.4, 1.1 Hz, 2H), 3.64 (t, J=8.4 Hz, 2H), 4.47 (bs, 1H), 7.31 (m, 1H), 7.85 (dt, J=2.1, 0.9 Hz, 1H).

1-Benzenesulfonyl-5-bromo-2,3-dihydro-1H-pyrrolo[2,3-b]pyridine (6)

[0294]  [see pdf for image]
[0295] To a 0° C. stirred solution of 5-bromo-azaindoline 5 (150 mg, 0.75 mmol) in N,N-dimethylacetamide (7 mL) was added in one portion 60% dispersion of NaH in mineral oil (38 mg, 0.94 mmol). After 0.5 h benzenesulfonyl chloride (0.12 mL, 0.94 mmol) in N,N-dimethylacetamide (1 mL) was added dropwise, and the mixture allowed to slowly warm to r.t. After 2 days the mixture was partitioned between AcOEt-brine. The aqueous layer was extracted with AcOEt (2×). The combined organic solutions were dried (MgSO4), filtered and concentrated. The residue was purified by preparative TLC (PTLC) with CH2Cl2 as eluent to afford the azaindoline 6 (21 mg, 8%) as a solid. 1H NMR (400 MHz; CDCl3) δ 3.04 (t, J=8.6 Hz, 2H), 4.08 (t, J=8.6 Hz, 2H), 7.45-7.51 (m, 3H), 7.56-7.60 (m, 1H), 8.08 (m, 2H), 8.18 (m, 1H).
[0296] Use of 5-bromo-7-azaindoline 4 in the metal-halogen exchange and subsequent reactions

Reaction with Alkyl Halides. Synthesis of 5-methyl Derivative 9

[0297]  [see pdf for image]

1-(tert-Butyl-dimethyl-silanyl)-5-methyl-2,3-dihydro-1H-pyrrolo[2,3-b]pyridine (7)

[0298]  [see pdf for image]
[0299] To a stirred and cooled (−78° C.) solution of bromide 4 (0.20 g, 0.64 mmol) in Et2O (2.5 mL) was added dropwise a 1.5 M solution of tert-BuLi in pentane (0.89 mL, 1.34 mmol). After 38 min MeI (0.1 mL, 1.61 mmol) was added dropwise and the mixture allowed to gradually warm to r.t. After 12 h the mixture was partitioned between CHCl3 and saturated aqueous NaHCO3 solution. The aqueous layer was extracted with CHCl3 (2×). The combined organic extracts were dried (MgSO4), and concentrated to afford 7 as a yellow oily residue, which was used directly in the next step without purification.

1-(tert-Butyl-dimethyl-silanyl)-5-methyl-1H-pyrrolo[2,3-b]pyridine (8)

[0300]  [see pdf for image]
[0301] To a stirred solution of the crude azaindoline 7 (0.64 mmol) in CH2Cl2 (10 mL) was added DDQ (145 mg, 0.64 mmol) in one portion. After 20 min the resulting black mixture was diluted with saturated aqueous NaHCO3 solution and stirred vigorously for 15 min. The aqueous layer was extracted with CHCl3 (2×) and the combined organic solutions were dried (MgSO4), filtered and concentrated to afford azaindole 8 as a brown oil, which was used directly in the next step without purification.

5-Methyl-1H-pyrrolo[2,3-b]pyridine (9)

[0302]  [see pdf for image]
[0303] To a stirred solution of the crude azaindole 8 (0.64 mmol) in MeOH (6 mL) was added a 10% solution of HCl in methanol (3 mL). After 20 min the mixture was concentrated and partitioned between AcOEt and saturated aqueous NaHCO3 solution. The aqueous layer was extracted with AcOEt (2×) and the combined organic solutions were dried (MgSO4), filtered and concentrated. The residue was purified by PTLC using 5% MeOH in CH2Cl2 to afford the desired methyl derivative 9 (68 mg, 81% over 3 steps). 1H NMR (400 MHz; CDCl3) δ 2.45 (s, 3H), 6.42 (d, J=3.4 Hz, 1H), 7.34 (d, J=3.4 Hz, 1H), 7.76 (d, J=1.7 Hz, 1H), 8.19 (d, J=1.7 Hz, 1H), 10.92 (br s, NH).

Reaction with CO2. Synthesis of Acid 12.

[0304]  [see pdf for image]

1-(tert-Butyl-dimethyl-silanyl)-2,3-dihydro-1H-pyrrolo[2,3-b]pyridine-5-carboxylic acid (10)

[0305]  [see pdf for image]
[0306] To a stirred and cooled (−78° C.) solution of the bromide 4 (205 mg, 0.65 mmol) in Et2O (4 mL) was added dropwise a 1.5 M solution of tert-butyllithium in pentane (0.92 mL, 1.37 mmol). After 40 min., dry gaseous CO2 was introduced into the reaction vessel. Progress of the reaction was followed by TLC analysis. After complete consumption of starting material 4 the reaction was quenched by the addition of saturated aqueous NaHCO3 solution. The mixture was allowed to warm to room temperature, and diluted with CH2Cl2. The aqueous layer was extracted with CH2Cl2 (2×), and the combined organic solutions were dried (MgSO4), filtered and concentrated. The residual yellow oil was dissolved in CH2Cl2:MeOH=20:1 and filtered through silicagel pad. The filtrate was concentrated and used directly in the next step.

1H-Pyrrolo[2,3-b]pyridine-5-carboxylic acid (12)

[0307]  [see pdf for image]
[0308] A solution of crude acid 10 in CH2Cl2 (5 mL) was treated with DDQ in small portions until TLC analysis revealed no starting material left. The mixture was concentrated to afford a solid residue containing azaindole 11. The residue was dissolved in a 5% solution of HCl in MeOH (5 mL), and stirred at r.t. After 1.5 h the mixture was concentrated and diluted with CHCl3 and saturated brine. The mixture was basified with 50% NaOH solution to pH 11. The organic layer was discarded. The aqueous layer was neutralized with 6 M HCl and extracted with AcOEt (4×). The combined organic extracts were dried (MgSO4), filtered and concentrated. The residue was purified by PTLC using CH2Cl2:MeOH=9:1 as eluent to afford acid 12 (3.19 mg, 3% over 3 steps). 1H NMR (400 MHz; CD3OD) δ 6.58 (d, J=3.5 Hz, 1H), 7.42 (d, J=3.5 Hz, 1H), 8.58 (d, J=2.0 Hz, 1H), 8.85 (d, J=1.7 Hz, 1H).

Reaction with DMF. Synthesis of Alcohol 15 and Aldehyde 16.

[0309]  [see pdf for image]

1-(tert-Butyl-dimethyl-silanyl)-2,3-dihydro-1H-pyrrolo[2,3-b]pyridine-5-carbaldehyde (13)

[0310]  [see pdf for image]
[0311] To a stirred and cooled (−78° C.) solution of the bromide 4 (5.00 g, 15.96 mmol) in Et2O (92 mL) was added dropwise 1.5 M solution of tert-butyllithium in pentane (22.3 mL, 33.5 mmol). After 45 min additional stirring at −78° C., DMF (5.6 mL, 72.3 mmol) was added dropwise, and the mixture was allowed to slowly warm to r.t. After 20 h the mixture was partitioned between saturated aqueous NaHCO3 solution and CH2Cl2. The organic layer was separated, dried (MgSO4), and concentrated to afford the crude aldehyde 13 (4.32 g). 1H NMR (400 MHz; CDCl3) δ 0.32 (s, 6H), 0.92 (s, 9H), 3.02 (m, 2H), 3.70 (m, 2H), 7.55 (d, J=2.0 Hz, 1H), 8.16 (d, J=2.0 Hz, 1H), 9.61 (s, 1H).

[1-(tert-Butyl-dimethyl-silanyl)-2,3-dihydro-1H-pyrrolo[2,3-b]pyridine-5-yl]-methanol (14)

[0312]  [see pdf for image]
[0313] To a stirred and cooled (0° C.) solution of crude 13 (2.77 g, 10.6 mmol) in EtOH (100 mL) was added NaBH4 (0.48 mg, 12.7 mmol) in a single portion. The mixture was allowed to warm to r.t. After 20 h the mixture was concentrated and partitioned between CH2Cl2-brine. The organic layer was dried (MgSO4) and concentrated. The residue was purified by SGC with CH2Cl2:MeOH as eluent (gradient up to 5% MeOH) to afford alcohol 14 (0.67 g, 24%). 1H NMR (400 MHz; CDCl3) δ 0.31 (s, 6H), 0.94 (s, 9H), 2.97 (t, J=8.2 Hz, 2H), 3.65 (t, J=8.2 Hz, 2H), 4.39 (s, 2H), 7.19 (s, 1H), 7.69 (s, 1H).

[1-(tert-Butyl-dimethyl-silanyl)-1H-pyrrolo[2,3-b]pyridin-5-yl]-methanol (15)

[0314]  [see pdf for image]
[0315] DDQ (53 mg, 0.23 mmol) was added in three equal portions to a stirred solution of alcohol 14 (54 mg, 0.20 mmol) in a mixture of CH2Cl2 (15 mL) and 0.2 M pH 7 phosphate buffer (0.15 mL). When TLC analysis showed complete consumption of the starting material, the mixture was diluted with saturated aqueous NaHCO3 (16 mL) and stirred vigorously for 1 h. Then the mixture was extracted with AcOEt (2×). The combined organic extracts were washed with saturated brine (1×), dried (MgSO4) and concentrated. The residue was purified by PTLC with benzene as eluent to afford alcohol 15 (16 mg, 31%). 1H NMR (400 MHz; CDCl3) δ 0.63 (s, 6H), 0.93 (s, 9H), 4.77 (s, 2H), 6.52 (d, J=3.5 Hz, 1H), 7.26 (d, J=3.5 Hz, 1H), 7.89 (d, J=2.0 Hz, 1H), 8.28 (d, J=2.0 Hz, 1H).

1-(tert-Butyl-dimethyl-silanyl)-1H-pyrrolo[2,3-b]pyridine-5-carbaldehyde (16)

[0316]  [see pdf for image]
[0317] To a stirred solution of the alcohol 13 (54 mg, 0.20 mmol) in a mixture of CH2Cl2 (15 mL) and 0.2 M pH 7 phosphate buffer (0.15 mL) was added DDQ (53 mg, 0.23 mmol) in three equal portions. When TLC analysis showed complete consumption of the starting material, the mixture was diluted with saturated aqueous NaHCO3 (16 mL) and stirred vigorously for 1 h. The mixture was then extracted with AcOEt (2×). The combined organic solutions were washed with saturated brine (1×), dried (MgSO4) and concentrated. The residue was purified by PTLC with benzene as eluent to afford aldehyde 16 (11 mg, 21%). 1H NMR (400 MHz; CDCl3) δ 0.66 (s, 6H), 0.94 (s, 9H), 6.67 (d, J=3.5 Hz, 1H), 7.34 (d, J=3.5 Hz, 1H), 8.37 (d, J=2.0 Hz, 1H), 8.76 (d, J=2.0 Hz, 1H), 10.11 (s, 1H).

1-(tert-Butyl-dimethyl-silanyl)-1H-pyrrolo[2,3-b]pyridine-5-carboxylic acid (11)

[0318]  [see pdf for image]
[0319] To a stirred and cooled (0° C.) solution of aldehyde 16 (115 mg, 0.44 mmol) in tert-butanol (3.1 mL) and 2-methyl-2-butene (0.77 mL) was added a solution of NaClO2 (194 mg, 2.1 mmol) and NaH2PO4.H2O (244 mg, 1.8 mmol) in water (2.31 mL) dropwise. When 16 was consumed (TLC) the mixture was partitioned between AcOEt and water. The organic layer was washed with saturated brine (1×), dried (MgSO4), filtered and concentrated to afford acid 11 (20 mg, 16%) as an off-white solid. 1H NMR (400 MHz; CDCl3) δ 0.66 (s, 6H), 0.94 (s, 9H), 6.65 (s, 1H), 7.32 (s, 1H), 8.61 (s, 1H) and 9.03 (s, 1H).

Metal-Metal Exchange—Stannylation. Synthesis of Benzyl Derivative 18.

[0320]  [see pdf for image]

1-(tert-Butyl-dimethyl-silanyl)-5-tributylstannanyl-2,3-dihydro-1H-pyrrolo[2,3-b]pyridine (17)

[0321]  [see pdf for image]
[0322] To a stirred and cooled (−90° C.) solution of bromide 4 (206 mg, 0.66 mmol) in THF (2.5 mL) was added dropwise 1.5 M solution of tert-butyllithium in pentane (1 mL, 1.51 mmol). After 35 min additional stirring at −90° C., tri-n-butyltin iodide (0.23 mL, 0.79 mmol) was added in one portion. The mixture was stirred at −90° C. for 10 min, −78° C. for 40 min, and then allowed to warm to r.t. The mixture was partitioned between AcOEt-brine. The aqueous layer was extracted with AcOEt (3×) and the combined organic solutions were dried (MgSO4), and concentrated to afford the crude stannane 17, which was used in the next step without purification.

5-Benzyl-2,3-dihydro-1H-pyrrolo[2,3-b]pyridine (18)

[0323]  [see pdf for image]
[0324] To a stirred solution of the crude stannane 17 (172 mg, 0.33 mmol) in THF (2.5 mL) was added PhCH2Br (0.03 mL, 0.27 mmol) and (Ph3P)2PdCl2 (5 mg, 0.007 mmol). The mixture was refluxed under N2 for 19 h, cooled, and partitioned between AcOEt-brine. The aqueous layer was extracted with AcOEt (2×). The combined organic solutions were dried (MgSO4), and concentrated in vacuum. The residual yellow oil was dissolved in MeOH (3 mL) and treated with a 10% solution of HCl in MeOH (2 mL). The mixture was stirred for 2.5 h, neutralized with saturated aqueous NaHCO3 solution and extracted with AcOEt (2×). The combined organic extracts were dried (MgSO4), concentrated, and purified by PTLC with CH2Cl2:MeOH=95:5 as eluent to afford the 5-benzyl derivative 18 (8 mg, 11% over 2 steps). 1H NMR (400 MHz; CDCl3) δ 2.99 (t, J=8.1 Hz, 2H), 3.60 (t, J=8.3 Hz, 2H), 3.79 (s, 2H), 7.06-7.31 (m, 7H), 7.69 (br s, NH).

Reaction with Aldehyde. Synthesis of Alcohol 19 and Ketone 20.

[0325]  [see pdf for image]

(2,3-Dihydro-1H-pyrrolo[2,3-b]pyridin-5-yl)-p-tolyl-methanol (19)

[0326]  [see pdf for image]
[0327] To a stirred and cooled (−78° C.) solution of the bromide 4 (100 mg, 0.32 mmol) in Et2O (1.8 mL) was added dropwise 1.5 M solution of tert-butyllithium in pentane (0.45 mL, 0.67 mmol). The mixture was stirred for an additional 0.6 h at −78° C., p-tolylaldehyde (0.04 mL, 0.32 mmol) was added, and the mixture slowly allowed to warm to r.t. After 18 h the mixture was partitioned between AcOEt-brine. The aqueous layer was extracted with AcOEt (2×). The combined organic solutions were dried (MgSO4), concentrated, and the residue was purified by PTLC with CH2Cl2:MeOH=95:5 as eluent to afford alcohol 19 (15 mg, 19%) as a white solid. 1H NMR (400 MHz; CDCl3) δ 2.34 (s, 3H), 5.99 (s, 1H), 6.45 (d, J=3.5 Hz, 1H), 7.16 (d, J=7.8 Hz, 2H), 7.30-7.32 (m, 3H), 7.93 (d, J=1.8 Hz, 1H), 8.32 (d, J=2.0 Hz, 1H) and 9.77 (br s, NH).

(1H-Pyrrolo[2,3-b]pyridin-5-yl)-p-tolyl-methanone (20)

[0328]  [see pdf for image]
[0329] To a stirred solution of the alcohol 20 (15 mg, 0.06 mmol) in CHCl3 (1.2 mL) was added activated MnO2 (5.4 mg, 0.06 mmol) in one portion. After 0.5 h the mixture was filtered through a pad of silica and the filtrate evaporated. The residue was purified by PTLC with CH2Cl2:MeOH=95:5 as eluent to afford ketone 20 (12.5 mg, 88%) as a white solid. 1H NMR (400 MHz; CDCl3) δ 2.47 (s, 3H), 6.63 (d, J=3.3 Hz, 1H), 7.32 (d, J=8.1 Hz, 2H), 7.44 (d, J=3.0 Hz, 1H), 7.75 (d, J=8.1 Hz, 2H), 8.43 (d, J=1.8 Hz, 1H), 8.83 (d, J=1.8 Hz, 1H) and 10.14 (br s, NH).

Reaction with Halosilanes. Synthesis of TMS Derivative 22.

[0330]  [see pdf for image]

5-Trimethylsilanyl-2,3-dihydro-1H-pyrrolo[2,3-b]pyridine (21)

[0331]  [see pdf for image]
[0332] To a stirred and cooled (−78° C.) solution of bromide 4 (600 mg, 1.91 mmol) in Et2O (10.8 mL) was added 1.5 M t-BuLi in pentane (2.68 mL, 4.02 mmol) dropwise, followed after 40 min by dropwise addition of TMSCl (0.36 mL, 3.83 mmol). The mixture was allowed to warm slowly to r.t. After 18 h the mixture was quenched by the addition of water and then extracted with AcOEt. The organic extract was washed with saturated brine, dried (MgSO4), filtered and concentrated to afford the crude disilylated azaindoline (508 mg). This was diluted with MeOH (15.6 mL) and 10% HCl (7.8 mL) and stirred vigorously for 20 min. The mixture was basified with saturated NaHCO3 solution and extracted with AcOEt (2×). The combined organic extracts were dried (MgSO4), and concentrated to afford the desired 21 (367 mg, quantitative over 2 steps). 1H NMR (400 MHz; CDCl3) δ 0.22 (s, 9H), 3.04 (m, 2H), 3.60 (t, J=8.3 Hz, 2H), 4.58 (br s, NH), 7.34 (m, 1H), 7.88 (m, 1H).

5-Trimethylsilanyl-1H-pyrrolo[2,3-b]pyridine (22)

[0333]  [see pdf for image]
[0334] To a stirred solution of the azaindoline 21 (20 mg, 0.10 mmol) in CH2Cl2 (2 mL) was added oven activated MnO2 (9 mg, 0.10 mmol) in one portion. After 18 h the mixture was filtered through a silica pad. The pad was washed with AcOEt and the combined organic solutions evaporated to afford the azaindole 22 (17 mg, 86%). 1H NMR (400 MHz; CDCl3) δ 0.35 (s, 9H), 6.50 (d, J=3.5 Hz, 1H), 7.35 (d, J=3.5 Hz, 1H), 8.10 (d, J=1.5 Hz, 1H), 8.40 (d, J=1.5 Hz, 1H), 10.62 (br s, NH).
[0335] Participation of 5-bromoindolines in Suzuki type reactions. Synthesis of 4-(dimethylamino)phenyl derivatives 23 and 24.
[0336]  [see pdf for image]

[4-(2,3-Dihydro-1H-pyrrolo[2,3-b]pyridin-5-yl)-phenyl]-dimethyl-amine (23)

[0337]  [see pdf for image]
[0338] A mixture of 5 (29.0 g, 0.146 mol), 4-(dimethylamino)phenylboronic acid (36.05 g, 0.218 mol), LiCl (18.5 g, 0.441 mol), (PPh3)2PdCl2 (8.60 g, 12.3 mmol) and 10% aqueous Na2CO3 (364 mL) in EtOH (870 mL):toluene (870 mL) was refluxed for 1 h 30 min. The reaction mixture was cooled to r.t., and poured into AcOEt:brine. The organic layer was separated and the aqueous layer was extracted with CH2Cl2 (10×500 mL). Combined organic solutions were dried (MgSO4), concentrated and redissolved in CH2Cl2 (1.5 L). The solution was mixed with silicagel (250 mL; Kieselgel 60, 230-400 mesh). Solvent was evaporated and the residual solid loaded on a silicagel column for separation. Purification by means of SGC with CH2Cl2:MeOH as eluent afforded 17.25 g (49%) of desired 23 as tan powder. 1H NMR (400 MHz, CDCl3) δ 2.98 (s, 6H), 3.11 (tt, J=8.3, 1.0 Hz, 2H), 3.65 (t, J=8.3 Hz, 2H), 4.44 (bs, 1H), 6.79 (d, J=8.8 Hz, 2H), 7.38 (d, J=8.8 Hz, 2H), 7.46 (dt, J=2.0, 1.2 Hz, 1H), 8.02 (dt, J=2.0, 0.9 Hz, 1H).

Dimethyl-[4-(1H-pyrrolo[2,3-b]pyridin-5-yl)-phenyl]-amine (24) and methyl-[4-(1H-pyrrolo[2,3-b]pyridin-5-yl)-phenyl]-amine (25)

[0339]  [see pdf for image]
[0340] To a solution of 23 (11.5 g, 48.5 mmol) in CH2Cl2 (1 L) was added portionwise over 2 h solid MnO2 (˜75 g, activated by heating at 130° C.) until the TLC showed no starting material remaining. The reaction mixture was filtered and the filtrate concentrated. The residual dark brown solid was purified by SGC using AcOEt:hexane (1:1, dry loading) as eluent to afford 24 (9.50 g, 83%) as a light orange solid; 1H NMR (400 MHz, CDCl3) δ 3.04 (s, 6H), 6.56 (dd, J=3.4, 1.6 Hz, 1H), 6.89 (d, J=8.8 Hz, 2H), 7.41 (dd, J=3.4, 2.3 Hz, 1H), 7.57 (d, J=8.8 Hz, 2H), 8.12 (d, J=2.1 Hz, 1H), 8.58 (d, J=2.1 Hz, 1H), 10.40-10.60 (bs, NH). The 1H NMR also showed a small amount of 25 (about 8% mol), which could not be separated from 24.
[0341] Participation of 5-bromoindoles in Suzuki type reactions. Synthesis of 5-substituted 7-azaindoles 24, 28, and 29.
[0342]  [see pdf for image]

5-Bromo-1-(tert-butyl-dimethyl-silanyl)-1H-pyrrolo[2,3-b]pyridine (26)

[0343]  [see pdf for image]
[0344] DDQ (about 380 mg, 1.68 mmol) was added in portions to a solution of 4 (525 mg, 1.68 mmol) in a mixture of CH2Cl2 (90 mL) and 0.2 M phosphate buffer pH 7 solution (910 μL) until full consumption of the starting material (TLC). Then, saturated aqueous NaHCO3 solution (22 mL) was added, and the reaction mixture stirred for 0.5 h. The organic layer was separated and the aqueous layer was extracted with CH2Cl2 (3×20 mL). The combined organic solutions were dried (MgSO4), concentrated and purified by SGC with hexane:CH2Cl2 as eluent (in gradient up to 20% CH2Cl2) to give 26 (505 mg, 97%) as a clear oil; 1H NMR (400 MHz, CDCl3) δ 0.62 (s, 6H), 0.93 (s, 9H), 6.47 (d, J=3.5 Hz, 1H), 7.24 (d, J=3.5 Hz, 1H), 7.97 (d, J=2.2 Hz, 1H), 8.28 (d, J=2.2 Hz, 1H).

5-Bromo-1H-pyrrolo[2,3-b]pyridine (27)

Method 1—from 26

[0345]  [see pdf for image]
[0346] To a stirred solution of the TBS derivative 26 (1.01 g, 3.3 mmol) in MeOH (10 mL) was added a 10% solution of HCl in MeOH (7 mL). After 8 min the solvents were evaporated and the residue was partitioned between AcOEt and saturated aqueous NaHCO3. The aqueous layer was extracted with AcOEt (3×). The combined organic solutions were dried (MgSO4), concentrated and purified by PTLC with CH2Cl2:MeOH=95:5 as eluent to afford the bromo derivative 27 (0.60 g, 94%). 1H NMR (400 MHz; CDCl3) δ 6.47 (dd, J=2.0, 3.5 Hz, 1H), 7.37 (dd, J=2.5, 3.5 Hz, 1H), 8.08 (d, J=2.0 Hz, 1H), 8.36 (d, J=2.0 Hz, 1H), 10.24 (br s, H).

Method 2—from 5

[0347]  [see pdf for image]
[0348] To a stirred solution of azaindoline 5 (7.00 g, 35.2 mmol) in CH2Cl2 (664 mL) was added activated MnO2 (3.06 g, 35.2 mmol), and progress of the reaction was monitored by 1H NMR of reaction aliquots. After 3 days the mixture was filtered through a pad of silica, and the pad was washed with EtOAc. The filtrates were concentrated to afford the azaindole 27 (6.98 g, 100%) as a brown solid. 1H NMR data as in Method 1.

Dimethyl-[4-(1H-pyrrolo[2,3-b]pyridin-5-yl)-phenyl]-amine (24)

[0349]  [see pdf for image]
[0350] A mixture of bromide 27 (6.00 g, 30.4 mmol), lithium chloride (3.84 g, 90.8 mmol), 4-(N,N-dimethylaminophenyl)boronic acid (7.53 g, 45.7 mmol), toluene (171 mL), EtOH (171 mL), 1 M aqueous Na2CO3 solution (76.2 mL, 76.2 mmol) and (PPh3)2PdCl2 (60 mg, 0.080 mmol) was refluxed (bath temp. 105° C.) in the dark under nitrogen for 22 h. The mixture was then concentrated to dryness and the residue partitioned between CH2Cl2-water. The layers were separated and the aqueous layer was extracted with CH2Cl2. The combined organic solutions were dried (MgSO4), concentrated and purified by SGC using AcOEt as eluent to afford the product 24 (6.32 g, 88%) as a pale yellow solid. 1H NMR (400 MHz; CDCl3) δ 2.98 (s, 6H), 3.11 (tt, J=8.3, 1.0 Hz, 2H), 3.65 (t, J=8.3 Hz, 2H), 4.44 (bs, 1H), 6.79 (d, J=8.8 Hz, 2H), 7.38 (d, J=8.8 Hz, 2H), 7.46 (dt, J=2.0, 1.2 Hz, 1H), 8.02 (dt, J=2.0, 0.9 Hz, 1H).

5-[2-(4-Trifluoromethyl-phenyl)-vinyl]1H-pyrrolo[2,3-b]pyridine (28)

[0351]  [see pdf for image]
[0352] To a solution of bromide 27 (76 mg, 0.39 mmol), lithium chloride (49 mg, 1.16 mmol), trans-2[4-(trifluoromethyl)-phenyl]vinyl boronic acid (125 mg, 0.58 mmol) in a mixture of toluene (3 mL), EtOH (3 mL) and 1 M aqueous Na2CO3 solution (0.96 mL, 0.96 mmol) was added (PPh3)2PdCl2 (27 mg, 0.04 mmol) in one portion. The mixture was heated in the dark to 105° C. under a nitrogen atmosphere for 20 h, filtered through a pad of cotton wool and concentrated. The residue was purified by PTLC with CH2Cl2:MeOH=98:2 as eluent to afford styrene 28 (51 mg, 46%) as a pale yellow solid. 1H NMR (400 MHz; CDCl3) δ 6.55 (dd, J=2.0, 3.5 Hz, 1H), 7.15 (d, J=16.3 Hz, 1H), 7.31 (d, J=16.3 Hz, 1H), 7.35 (m, 1H), 7.62 (s, 4H), 8.13 (d, J=1.8 Hz, 1H), 8.50 (m, 1H), 9.17 (br s, NH).

{4-[1-(tert-Butyl-dimethyl-silanyl)-1H-pyrrolo[2,3-b]pyridin-5-yl]-phenyl}-dimethyl-amine (29)

[0353]  [see pdf for image]
[0354] A mixture of bromide 26 (500 mg, 1.61 mmol), lithium chloride (204 mg, 4.82 mmol), 4-(N,N-dimethylaminophenyl)boronic acid (398 mg, 1.61 mmol), toluene (9.6 mL), EtOH (9.6 mL), 1 M aqueous Na2CO3 solution (4.0 mL, 4.0 mmol) and (PPh3)2PdCl2 (95 mg, 0.135 mmol) was stirred in the dark under nitrogen at r.t. overnight and at 105° C. for 1 h. The mixture was then partitioned between AcOEt (20 mL) and brine (20 mL). The layers were separated and the aqueous layer was extracted with AcOEt (3×20 mL). The combined organic solutions were dried (MgSO4), concentrated and purified by SGC using hexane:CH2Cl2 as eluent (up to 30% CH2Cl2) to give 29 as a white solid (423 mg, 75%); 1H NMR (400 MHz, CDCl3) δ 0.56 (s, 6H), 0.87 (s, 9H), 2.89 (s, 6H), 6.45 (d, J=3.5 Hz, 1H), 6.74 (d, J=8.8 Hz, 2H), 7.15 (d, J=3.4 Hz, 1H), 7.44 (d, J=8.8 Hz, 2H), 7.90 (d, J=2.3 Hz, 1H), 8.42 (d, J=2.2 Hz, 1H).

Participation of 5-bromoindoles in the Stille Reaction. Synthesis of Thiophene Derivative 30.

5-Thiophen-2-yl-1H-pyrrolo[2,3-b]pyridine (30)

[0355]  [see pdf for image]
[0356] A solution of bromide 26 (150 mg, 0.48 mmol), 2-(tributylstannyl)thiophene (270 mg, 0.72 mmol), tri-o-tolylphosphine (29 mg, 0.10 mmol) and PdCl2(MeCN)2 (12.5 mg, 0.05 mmol) in toluene (3 mL) was stirred at 85° C. for 18 h under N2. The mixture was partially purified by PTLC using hexane:AcOEt=200:1 to afford a mixture of the desired product 30 and tin-containing impurities (205 mg). This mixture was dissolved in CHCl3 and extracted with 10% aqueous HCl (4×). The combined aqueous solutions were washed with CHCl3 (3×) and basified to pH 12 with 50% NaOH. The aqueous layer was extracted with CHCl3 (3×) and the combined organic extracts dried (MgSO4), filtered and evaporated to afford the azaindole 30 (22.7 mg, 23%) as a white solid. 1H NMR (400 MHz; CDCl3) 6.55 (dd, J=3.5, 1.8 Hz, 1H), 7.13 (dd, J=5.2, 3.5 Hz, 1H), 7.30-7.33 (m, 2H), 7.41 (dd, J=3.5, 2.4 Hz, 1H), 8.16 (d, J=2.0 Hz, 1H), 8.64 (br s, 1H), 10.45 (br s, NH).
[0357] Palladium-catalysed installation of boronic acid/ester functionality at C(5) of the 7-azaindole system. Synthesis of 5-(hetero)aryl derivatives 33, 35 and 37 via Suzuki reaction.

5-(4,4,5,5-Tetramethyl-[1,3,2]dioxaborolan-2-yl)-1H-pyrrolo[2,3-b]pyridine (31)

[0358]  [see pdf for image]
[0359] A mixture of 27 (500 mg, 2.54 mmol), [1,1′-bis(diphenylphosphino)ferrocene]dichloropalladium. HCl complex [PdCl2(dppf)] (24.0 mg, 0.0298 mmol), bis(pinacolato)diboron (966 mg, 3.81 mmol) and potassium acetate (747 mg, 7.61 mmol) in DMF (15 mL) were heated at 80° C. overnight. More palladium catalyst (24 mg) was added and the stirring continued overnight. The reaction mixture was cooled, poured onto water, extracted with ethyl acetate. The combined organic extracts were dried (MgSO4) and concentrated. The residual solid was extracted with diethyl ether. The solution was concentrated to give 31 as a tan solid (650 mg, 112%).

5-(2-Phenoxy-pyridin-3-yl)-1H-pyrrolo[2,3-b]pyridine (33)

[0360]  [see pdf for image]
[0361] A mixture of pinacol ester 31 (200 mg, 0.88 mmol), iodide 32 (390 mg, 1.32 mmol), LiCl (112 mg, 2.63 mmol), PdCl2(PPh3)2 (62 mg, 0.088 mmol), 1.0 M aq. Na2CO3 (2.2 mL, 2.19 mmol) in EtOH (4.0 mL) and toluene (4.0 mL) were refluxed for 5 h. After cooling the reaction mixture was partitioned between EtOAc/brine. The aqueous layer was extracted with more EtOAc (2×) and the combined organic extracts were dried (MgSO4) and concentrated. The residue was purified by silicagel chromatography using EtOAc:hexane (1:1) (gradient elution) to give 33 (106 mg, 42%); 1H NMR (400 MHz, CDCl3) δ 6.26 (bs, 4H), 6.55 (s, 1H), 7.38 (bs, 3H), 7.82 (s, 1H), 8.18 (s, 1H), 8.27 (s, 1H), 8.62 (s, 1H), 10.73 (bs, NH).

Pyrimidin-2-yl-[2-(1H-pyrrolo[2,3-b]pyridin-5-yl)-phenyl]-amine (35)

[0362]  [see pdf for image]
[0363] According to the above protocol, 31 (100 mg, 0.438 mmol), 34 (164 mg, 0.658 mmol), LiCl (56 mg, 1.32 mmol), PdCl2(PPh3)2 (31 mg, 0.0438 mmol), and 1.0 M aq. Na2CO3 (1.10 mL, 1.10 mmol) in EtOH (2.6 mL) and toluene (2.6 mL) were refluxed for 24 h. Product 35 was isolated by silicagel chromatography using EtOAc:hexane (3:2) (gradient elution) as a light orange foam (45.7 mg, 36%); 1H NMR (400 MHz, CDCl3) δ 6.33 (dd, J=3.5, 2.0 Hz, 1H), 6.69 (t, J=4.8 Hz, 1H), 7.17 (dt, J=8.7 Hz, 1.2 Hz, 1H), 7.23 (dd, J=5.8 Hz, 2.4 Hz, 1H), 7.29 (dd, J=7.6, 1.6 Hz, 1H), 7.42 (dt, J=8.4, 1.6 Hz, 1H), 7.89 (d, J=2.0 Hz, 1H), 8.05 (bs, NH), 8.16 (d, J=2.0 Hz, 1H), 8.28 (dd, J=8.2 Hz, 1.0 Hz, 1H), 8.40 (d, J=4.8 Hz, 2H), 11.02 (bs, NH).

[2-(1H-Pyrrolo[2,3-b]pyridin-5-yl)-phenyl]-carbamic acid tert-butyl ester (37)

[0364]  [see pdf for image]
[0365] Reaction was performed following the above protocol and using 31 (200 mg, 0.88 mmol), 36 (477 mg, 1.75 mmol), LiCl (112 mg, 2.63 mmol), PdCl2(PPh3)2 (62 mg, 0.088 mmol), 1.0 M aq. Na2CO3 (2.19 mL, 2.19 mmol) in EtOH (5.2 mL) and toluene (5.2 mL) with refluxing overnight. Silicagel chromatography using EtOAc:hexane (1:4) (gradient elution) afforded 37 as an orange oil (187 mg, 69%); 1H NMR (400 MHz, CDCl3) δ 1.25 (s, 9H), 6.48 (bs, NH), 6.57 (dd, J=3.5, 1.9 Hz, 1H), 7.12 (dt, J=7.5, 1.1 Hz, 1H), 7.23 (d, J=7.4 Hz, 1H), 7.39 (dt, J=8.6, 1.7 Hz, 1H), 7.42 (t, J=3.3 Hz, 1H), 7.93 (d, J=1.9 Hz, 1H), 8.12 (d, J=8.3 Hz, 1H), 8.30 (d, J=1.4 Hz, 1H), 10.09 (bs, NH).
[0366] Installation of boronic acid/ester functionality at C(5) of the 7-azaindole system via 5-lithio derivative. Synthesis of 5-(hetero)aryl derivative 41 using Suzuki reaction.
[0367]  [see pdf for image]
Synthesis of Boronic Derivative 38
[0368]  [see pdf for image]
[0369] To n-BuLi (0.54 mL, 1.35 mmol, 2.5M in hexane) in THF (4.0 mL), cooled to −78° C., was added dropwise a solution of 26 (200 mg, 0.624 mmol) in THF (1.0 mL) and the solution stirred at −78° C. for 10 min. Trimethyl borate (87 μL, 0.77 mmol) was added in one portion and the reaction mixture stirred at −78° C. for 1 h then at room temperature for 2 h. The reaction mixture was poured onto a mixture of saturated aq. NaHCO3/ethyl acetate. The organic layer was separated and the aqueous aqueous phase extracted with ethyl acetate (2×). The combined organic solutions were washed with water, dried (MgSO4) and concentrated to give product 38 as an oil (200 mg). LCMS of 38 showed a mixture of boronic acid and its methyl ester.

1-(tert-Butyl-dimethyl-silanyl)-5-[2-(pyrimidin-2-yloxy)-phenyl]-1H-pyrrolo[2,3-b]pyridine (40)

[0370]  [see pdf for image]
[0371] A mixture of 38 (100 mg, 0.36 mmol), iodide 39 (72 mg, 0.24 mmol), LiCl (31 mg, 0.72 mmol), PdCl2(PPh3)2 (31 mg, 0.024), 1M aq. Na2CO3 (603 μL, 0.60 mmol) in toluene (1.66 mL) and EtOH (1.66 mL) was refluxed for 5 h. The reaction mixture was cooled, poured onto ethyl acetate/brine and the aqueous phase extracted with more ethyl acetate (2×). The combined organic solutions were dried (MgSO4) and concentrated. The residue was partially purified by preparative TLC (4×1 mm, 60% ethyl acetate in hexane eluent) to give 40 (120 mg, 124%).

5-[2-(Pyrimidin-2-yloxy)-phenyl]-1H-pyrrolo[2,3-b]pyridine (41)

[0372]  [see pdf for image]
[0373] A mixture of 40 prepared above (120 mg, approx. 0.24 mmol), MeOH (1.1 mL) and 10% aq. HCl (2.4 mL) were stirred at room temperature for 1 h then poured onto saturated aq. NaHCO3/ethyl acetate. The aqueous phase was extracted with more ethyl acetate and the combined organic extracts dried (MgSO4) and concentrated to give pure product 41 (40.8 mg, 44% over 3 steps from 26); 1H NMR (400 MHz, CDCl3) δ 6.40 (dd, J=3.4, 1.6 Hz, 1H), 6.76 (t, J=4.8 Hz, 1H), 7.21 (m, 2H), 7.32 (dt, J=7.8 Hz, 1.8 Hz, 1H), 7.39 (dt, J=7.8, 1.8 Hz, 1H), 7.46 (dd, J=7.5, 1.8 Hz, 1H), 8.04 (d, J=2.0 Hz, 1H), 8.30 (d, J=4.8 Hz, 2H), 8.37 (d, J=2.0 Hz, 1H), 10.26 (bs, NH).
[0374] Installation of stannane at C(5) of the 7-azaindole system via 5-lithio derivative.

Synthesis of 5-(hetero)aryl Derivative 43 Using Stille Reaction.

[0375]  [see pdf for image]

1-(tert-Butyl-dimethyl-silanyl)-5-tributylstannanyl-1H-pyrrolo[2,3-b]pyridine (42)

[0376]  [see pdf for image]
[0377] To 2.5 M n-BuLi in hexane (0.67 mL, 1.69 mmol) in THF (5 mL), cooled to −78° C., was added a solution of 26 (0.25 g, 0.80 mmol) in THF (1.0 mL) dropwise. The solution was stirred at −78° C. for 10 min then a solution of Bu3SnI (446 mg, 0.96 mmol) in THF (0.5 mL) was added in one portion. The reaction mixture was stirred at −78° C. for 1 h then at room temperature for 2 h, then poured onto a mixture of ethyl acetate/saturated aq. NaHCO3. The aqueous phase was extracted with more ethyl acetate (2×). The combined organic solutions were dried (MgSO4) and concentrated to give stannane 42 as a light orange oil (483 mg, 115%); 1H NMR (400 MHz, CDCl3) δ 0.71 (s, 6H), 0.98 (t, J=7.4 Hz, 9H), 1.02 (s, 9H), 1.15-1.70 (m, 18H), 6.56 (d, J=3.5 Hz, 1H), 7.26 (d, J=3.5 Hz, 1H), 8.01 (d, J=1.4 Hz, 1H), 8.33 (d, J=1.4 Hz, 1H).

5-(3-Fluoro-phenyl)-1H-pyrrolo[2,3-b]pyridine (15)

[0378]  [see pdf for image]
[0379] A mixture of stannane 42 (200 mg, 0.384 mmol), 1-fluoro-3-iodobenzene (170 mg, 0.767 mmol), PdCl2(MeCN)2, and P(o-tolyl)3 in toluene (3.3 mL) were heated at 85° C. overnight. The reaction mixture was diluted with ethyl acetate, extracted with 10% aq. HCl (4×1 mL) and the HCl extracts basified with saturated aq. NaHCO3, then extracted with ethyl acetate (3×). The combined organic extracts were dried (MgSO4) and concentrated. Purification by preparative TLC (1 mm plate, 60% ethyl acetate in hexane eluent) afforded 43 (8.0 mg, 10%); 1H NMR (400 MHz, CDCl3) δ 6.57 (dd, J=3.5, 1.7 Hz, 1H), 7.06 (m, 1H), 8.13 (d, J=2.1 Hz, 1H), 7.34 (m, 1H), 7.42 (m, 3H), 8.56 (d, J=2.1 Hz, 1H), 10.66 (bs, NH).

Synthesis of Ketone 45

[0380]  [see pdf for image]

5-(4,4,5,5-Tetramethyl-[1,3,2]dioxaborolan-2-yl)-1H-pyrrolo[2,3-b]pyridine (44)

[0381]  [see pdf for image]
[0382] The 5-bromo-7-azaindole 27 (0.5 g, 2.54 mmol), bis(pinacolato)diboron (0.968 g, 3.81 mmol), potassium acetate (0.748 g, 7.61 mmol), [1,1′-bis(diphenylphosphino)ferrocene]dichloropalladium(II) complex with CH2Cl2 (1:1) (49 mg, 0.06 mmol) and DMF (11 mL) were heated in a sealed tube at 80° C. After 44 h, the reaction mixture was allowed to cool to room temperature, diluted with EtOAc and saturated brine, and partitioned. The aqueous layer was extracted with EtOAc (3×). The combined organic extracts were washed with brine (1×), dried (MgSO4), filtered and concentrated in vacuo. The crude pinacol ester 44 was used directly for the next step without any further purification. 1H NMR (400 MHz; CDCl3) δ 1.38 (s, 12H), 6.51 (d, J=3.5 Hz, 1H), 7.32 (d, J=3.5 Hz, 1H), 8.42 (d, J=1.2 Hz, 1H), 8.63 (d, J=1.2 Hz, 1H) and 10.59 (brs, NH).

(3,4-Dimethoxy-phenyl)-(1H-pyrrolo[2,3-b]pyridin-5-yl)-methanone (45)

[0383]  [see pdf for image]
[0384] To the crude pinacol ester 44 (310 mg, 1.27 mmol) in dry toluene (25 mL) was sequentially added cesium carbonate (2.07 g, 6.35 mmol), tetrakis(triphenylphosphine)palladium(0) (73 mg, 0.06 mmol) and 3,4-dimethoxybenzoyl chloride (510 mg, 2.54 mmol). The mixture was heated at 100° C. in the dark. After 28 h a further portion of tetrakis(triphenylphosphine)palladium(0) (90 mg, 0.08 mmol) was added. Following another 22 h the mixture was allowed to cool to ambient temperature and diluted with EtOAc and water and partitioned. The organic layer was washed with saturated sodium hydrogen carbonate, saturated brine, dried (MgSO4), filtered and concentrated. The crude residue was purified by preparative LCMS (column LUNA 10μ C18(2) 00G-4253-V0 250×50 mm) using water—acetonitrile (0.1% AcOH) as eluent (in gradient; flow 80 mL/min) to afford ketone 45 [12.6 mg, 3.6% (2 steps)] as a white solid. 1H NMR (400 MHz; CDCl3) δ 3.99 (s, 3H), 4.00 (s, 3H), 6.54 (dd, J=2.0 and 3.5 Hz, 1H), 6.98 (d, J=8.5 Hz, 1H), 7.38 (dd, J=2.5 and 3.5 Hz, 1H), 7.71 (d, J=2.0 Hz, 1H), 7.81 (dd, J=0.7 and 2.5 Hz, 1H), 7.93 (dd, J=2.0 and 8.5 Hz, 1H), 8.22 (d, J=2.5 Hz, 1H) and 8.90 (brs, NH).
(57)

Claims

1. A compound of formula (I)
[see pdf for image]
wherein X is R1S(O)2, (R1)3Si, R1C(O), R1OCH2, R12NSO2, R1OC(O)—, R1(R1O)CH—, R1CH2CH2—, R1CH2—, PhC(O)CH2—, CH2═CH—, ClCH2CH2—, Ph3C—, Ph2(4-pyridyl)C—, Me2N—, HO—CH2—, R1OCH2—, (R1)3SiOCH2—, (R1O)2CH—, t-BuOC(O)CH2—, Me2NCH2— and tetrahydropyranylamine;
wherein R1 is C1-6 alkyl, C3-12 cycloalkyl, C1-6 haloalkyl, or C6-12 carbocyclyl; optionally substituted with one or more of C1-6 alkyl, Si(R3)3, OR3, NO2, CO2, CO2R3, halogen, haloalkyl, SR3, CN, NR3COR3, COR13CONR3R3,
wherein R3 is hydrogen or C1-6 alkyl,
with the proviso that when X is R1OC(O)—, R1 is not PhCH2.
2. The compound of claim 1, wherein X is (R1)3Si or R1OCH2, and R1 is C1-6 alkyl or C6-12 aryl.
3. The compound of claim 1, wherein X is (R1)3Si and R1 is methyl, ethyl, propyl, butyl or phenyl.
4. The compound of claim 1, wherein X is TBS.
5. The compound of claim 1, wherein X is PhSO2.
6. A method for synthesizing a compound of formula (I) as claimed in claim 2, comprising brominating a compound of formula (II);
[see pdf for image]
wherein X is (R1)3Si or R1OCH2, and R1 is C1-6 alkyl or C6-12 aryl.
7. A method as claimed in claim 6 wherein the bromination is carried out using Br2, dioxane dibromide, pyridinium perbromide or NBS.
8. A method as claimed in claim 6 wherein X is (R1)3Si and R1 is methyl, ethyl, propyl, butyl or phenyl.
9. A method as claimed in claim 7 wherein X is (R1)3Si and R1 is methyl, ethyl, propyl, butyl or phenyl.
*****

Download Citation


Sign in to the Lens

Feedback